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2
bilization approach described herein offers a significant
advantage of Versatility in sensor fabrication.
The present invention provides compounds that form self
assembled monolayers that are useful in the fabrication of
biosensors. In particular, the present invention provides self
assembled monolayers comprising compounds of Formula I

SELF-ASSEMBLED MONOLAYERS AND
METHODS FOR USING THE SAME IN
BOSENSINGAPPLICATIONS
GRANT SUPPORT

This work was supported in part by the National Science
Foundation (NSF Grant EPSCoR RII (2010-2015)). The
Government may have certain rights in the invention, as
specified by law.

or II:
10

FIELD OF THE INVENTION

The present invention relates to new self-assembled mono
layers (SAMs) that are useful in the fabrication of biosensors.

15

II

BACKGROUND OF THE INVENTION

The present invention relates to biosensors that are capable
of rapidly quantifying the concentration of biomolecules in a
sample solution with high accuracy in a simplified manner,
and to methods of producing same.
The detection of a ligand by a receptor (for example, detec
tion of a hormone, an antigen or a pathogenic agent) is impor
tant in the diagnosis of diseases and finding of useful biomol
ecules. Many rapid test methods for detecting ligands with
high selectivity and sensitivity have been developed. These
include radio-activity-based assays, chemiluminescence
assays, magnetic based assays, and fluorescence or colori
metric assays. Immunoassays, such as enzyme-linked immu
nosorbent assay (ELISA), enzyme immunoassay (EIA), and
radioimmunoassay (RIA), are also well known for the detec
tion of ligands Such as hormones, antigens or antibodies. The
basic principle in many of these assays is that a marker
conjugated (for example, an enzyme-, chromogen-, fluoro
gen-, or radionucleotide-conjugated) antibody permits anti
gen detection upon antibody binding. In order for this
interaction to be detected as a change in color, fluorescent or
radioactive complexes, significant numbers of antibodies
must be bound to a correspondingly large number of antigen
epitopes. The resulting labeled binding complex often must

25

30

35

40

be isolated from the labeled marker molecules for detection.

Although the prior art methods for measuring biological
analytes of interest are useful, many problems arise in the
application of these methods in biosensor platforms, such as
low sensitivity, selectivity and stability of the sensing device.
Moreover, existing methods are often time intensive, tedious
and costly. Accordingly, there remains a need for sensitive
and robust screening methods for detecting biomolecules in a
sample.

s/X-R,
as

R-V

2

Y-R

wherein constituent members are provided herein below.
The present invention further provides a method for detect
ing one or more biomolecules in a sample which comprises
the steps of (a) providing a component that comprises a self
assembled monolayer comprising a compound of Formula I
or II; (b) binding a multivalent cation to the monolayer; (c)
capturing a binding partner onto the monolayer, wherein the
binding partner comprises a detectable marker and a moiety
capable of binding the multivalent cation; (d) exposing the
sample to the monolayer component; and (e) detecting a
signal of the detectable marker.
The present invention further provides methods for detect
ing any ligand for a binding partner, Such as, without limita
tion, Small-molecules, hormones, proteins, peptides, nucleic
acids, lipids, antigens or antibodies.
The present invention further provides methods for detect
ing specific ligands Such as anti-peanutantigen and anti-HIV
p24 antibody.
The present invention further provides a kit for detecting
one or more target molecules in a sample.
BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a schematic showing immobilization of a histi
dine-tagged methylene blue (His-MB) construct onto an
imidazole-nickel-bound self-assembled monolayer (SAM)
50

of the invention.

FIG. 2 depicts (A) alternating current Voltammograms
(ACVs) of His-MB immobilized on an imidazole-Ni SAM
before and after displacement by free imidazole; and (B) a
representative displacement/replacement plot for a His-MB
55

60

SUMMARY OF THE INVENTION

Applicants have found that, Surprisingly, a more conve
nient approach is to first assemble a self-assembled mono
layer (SAM) containing terminal reactive groups that may
serve as a platform onto which one can couple different
binding partners to the monolayer. The SAM-peptide immo

R-U

45

Electrochemical biosensors such as an electrochemical

peptide-based (E-PB) sensor offer a convenient way to con
jugate biosensing elements labelled with a redox molecule on
a gold-lectrode Surface. To date, the most straightforward
method to fabricate an E-PB sensor involves direct adsorption
of thiolated peptide probes onto the gold electrode surface.
Despite being a valuable probe immobilization strategy, con
ventional methods lacks general Surface modification versa
tility.

R

65

SAM.

FIG.3 depicts ACVs of a His-MB peptide-bound SAM in
the presence of varying concentrations of anti-peanut IgY.
FIG. 4 depicts ACVs of (A) His-MB immobilized on an
imidazole-Co SAM before and after displacement by free
imidazole; and (B) His-MB immobilized on an imidazole
Zn SAM before and after displacement by free imidazole.
FIG. 5 depicts ACVs of (A) His-MB immobilized on an
imidazole-Ni SAM before and after displacement by free
histamine; and (B) His-MB immobilized on an imidazole-Ni
SAM before and after displacement by free histidine.
FIG. 6 depicts ACVs of (A) His-MB immobilized on a
nitrolotriacetic acid-Ni SAM before and after displacement

US 9,079,835 B2
3
by free imidazole; and (B) His-MB immobilized on a 1,4,7triazacyclononane-Zn SAM before displacement by free imi
dazole.

FIG.7 depicts ACVs of a His-MB peptide-bound SAM in
the absence and presence of anti-p24 antibodies.
FIG. 8 depicts structures of three imidazole-containing

5

molecules of the invention.

FIG.9 depicts ACVs of His-MB immobilized on SAMs
fabricated using compounds C11-Im, dS1-Im, and dS2-Im.
FIG. 10 depicts ACVs of His-MB modified (A) dS1-Im
and (B) dS2-Im SAMs before and after displacement by
Ni(II), and after replacement by His-MB.
DETAILED DESCRIPTION

10

15

The instant invention provides, inter alia, self-assembled
monolayers (SAMs) that can be used to immobilize binding
partners such as peptides in the fabrication of electrochemical
peptide-based sensors.
Compounds
In some embodiments, the present invention provides a
self-assembled monolayer comprising a compound of For
mula I or II:
25

30

II

R-U

sas

X-R
35

sas

R-V

21

Y-R

wherein:

40

a dashed line indicates an optional bond;
R-R are each, independently, Coalkyl, SR, OH,
COR, heterocyclyl, heteroaryl, alkenyl, alkynyl, CN, N, or
halo;

Rs and R are each, independently, absent, H, or R.;
R is 0-2R groups.
X, Y, U, and V are each, independently, Coalkyl,
C2-20alkenyl, C2-20alkynyl, C-20alkyl ether, C2-20alkenyl
ether, or Coalkynyl ether,
R is H. Coalkyl, C(O)H, CO-(Coalkyl), SH, or
S(C-2alkyl);
R, is Co-ohydroxyl, Coheterocycloalkyl, Cs-oaryl,

45

In some embodiments, at least one of X, Y, U, and V is

Cisalkyl.

In some embodiments, at least one of X, Y, U, and V is

50

Coheteroaryl, or NR'R''.

R is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl,
hydroxyl, halo, haloalkyl, haloalkoxy, cyano, nitro, azido,
amino, alkylamino, dialkylamino, carboxy, carboxyalkyl
ester, carboxy aryl ester, aminocarbonyl, alkylaminocarbo
nyl, dialkylaminocarbonyl, Sulfonyl, aminosulfonyl, alky
laminosulfonyl, dialkylaminosulfonyl, arylsulfonyl, aryl
sulfinyl, alkylsulfonyl, or arylsulfonyl; and

55

Coalkyl.
In some embodiments, X, Y, U, and V are Coalkyl.
In some embodiments, X, Y, U, and V are Cisalkyl.
In some embodiments, X, Y, U, and V are C-alkyl.
In some embodiments, at least one of X, Y, U, and V is
C2-20alkynyl.
In some embodiments, at least one of X, Y, U, and V is

60

R and R' are each, independently selected from H, sub
stituted or unsubstituted alkyl,
or R and R' come together to form a 4-10-membered

substituted or unsubstituted heterocyclic ring.
In some embodiments, at least one of R-R is SR.
In some embodiments, at least one of R-R is S(C20alkyl), SC(O)(Coalkyl), SH, or S(Coalkyl).

4
In some embodiments, at least one of R-R is SH or
SC(O)(Coalkyl).
In some embodiments, at least one of R-R is SH.
In some embodiments, at least one of R-R is SC(O)
(C-20alkyl).
In some embodiments, at least one of R-R is SC(O)CH.
In some embodiments, R and R are SR.
In some embodiments, RandR are S(Coalkyl), SC(O)
(Coalkyl), SH, or S(Coalkyl).
In some embodiments, R and R are SH or
SC(O)(Coalkyl).
In some embodiments R and R are SH.
In some embodiments, R and R2 are SC(O)(Coalkyl).
In some embodiments, R and R are SC(O)CH.
In some embodiments, at least one of R-R is OH, C(O)
R. N. heterocyclyl, or heteroaryl.
In some embodiments, at least one of R-R is OH.
In some embodiments, at least one of R-R is heterocyclyl
or heteroaryl.
In some embodiments, at least one of R-R is heterocy
clyl.
In some embodiments, at least one of R-R is 1.4.7-triaza
cyclononanyl.
In some embodiments, at least one of R-R is heteroaryl.
In some embodiments, at least one of R-R is pyridyl or
imidazolyl.
In some embodiments, at least one of R-R is pyridyl.
In some embodiments, at least one of R-R is imidazolyl.
In some embodiments, at least one of R-R is azido.
In some embodiments, at least one of R-R is CN.
In some embodiments, R and ROH, C(O)R. N. hetero
cyclyl, or heteroaryl.
In some embodiments, R and Ra are OH.
In some embodiments, R and R are heterocyclyl or het
eroaryl.
In some embodiments, R and Ra are heterocyclyl.
In some embodiments, R and R are 1,4,7-triazacy
clononanyl.
In some embodiments, R and Ra are heteroaryl.
In some embodiments, RandR are pyridyl or imidazolyl.
In some embodiments, R and Ra are pyridyl.
In some embodiments, R and Ra are imidazolyl.
In some embodiments, R and Ra are azido.
In some embodiments, R and Ra are CN.
In some embodiments, at least one of X, Y, U, and V is
C1-20alkyl.

Calkynyl.
In some embodiments, X, Y, U, and V are Coalkynyl.
In some embodiments, X, Y, U, and V are Calkynyl.
In some embodiments, Rs and R are absent.
In some embodiments, R, is OR groups.
In some embodiments, the compound is a compound of
Formula I.

In some embodiments, the compound is a compound of
65

Formula II.

In some embodiments, the compound is a compound of
Formula I, wherein:

US 9,079,835 B2
6
X, Y, U, and V are each, independently, Coalkyl; and
R, is absent.
In some embodiments, the compound is a compound of

RandR are SR;
R and Rare OH:
X, Y, U, and V are each, independently, Coalkyl, and
Formula II, wherein:
Rs and R are absent.
In some embodiments, the compound is a compound of 5 R and R are SH or SCO (Coalkyl);
R and Ra are heteroaryl;
Formula I, wherein:
X, Y, U, and V are each, independently, Coalkyl; and
R and R are SH or SCO (Coalkyl);
R and Rare OH:
R, is absent.
X, Y, U, and V are each, independently, Cisalkyl; and 10 In some embodiments, the compound is a compound of
Formula II, wherein:
Rs and R are absent.
In some embodiments, the compound is a compound of
R and R are SH or SCO Calkyl:
R and Ra are imidazolyl;
Formula I, wherein:
X, Y, U, and V are each, independently, Cisalkyl, and
R and R are SH or SCOCH:
R and Rare OH:
R, is absent.
15
X and Y are Calkyl:
In some embodiments, the compound is a compound of
U, and V are Calkyl; and
Formula II, wherein:
R and R are SH or SCO Calkyl:
Rs and R are absent.
R and Ra are imidazolyl;
In some embodiments, the compound is a compound of
X and Y are each Calkyl:
Formula I, wherein:
U and V are each Calkyl; and
R and Rare SR;
R and Ra are OH:
R, is absent.
X, Y, U, and V are each, independently, Coalkyl, and
In some embodiments, the compound is a compound of
Rs and R are H.
Formula II, wherein:
In some embodiments, the compound is a compound of 25 R and R are SH or SCO (Coalkyl);
Formula I, wherein:
R and Ra are Coalkyl,
R and R are SH or SCO (Coalkyl);
X, Y, U, and V are each, independently, Coalkyl; and
R and Rare OH:
R, is absent.
X, Y, U, and V are each, independently, Cisalkyl; and
In some embodiments, the compound is a compound of
30
Rs and R are H.
Formula
II, wherein:
In some embodiments, the compound is a compound of
R
and
R are SH or SCO Calkyl:
Formula I, wherein:
R
and
Ra are Calkyl:
R and Rare SH or SCOCH:
X,
Y,
U,
and V are each C alkyl; and
R and Ra are OH:
R, is absent.
35
X and Y are Calkyl
In some embodiments, the compound is a compound of
U, and V are Calkyl; and
Formula
II, wherein:
Rs and R are H.
R and R are SH or SCO Calkyl;
In some embodiments, the compound is a compound of
R and Ra are pyridyl;
Formula I, wherein:
X and Y are each Calkynyl:
40
R and Rare SR;
U and V are each Calkynyl; and
R and Ra are heteroaryl;
X, Y, U, and V are each, independently, Coalkyl, and
R, is absent.
In some embodiments, the compound is a compound of
Rs and R are absent.
In some embodiments, the compound is a compound of Formula II, wherein:
45
Formula I, wherein:
R and R are SH or SCO (Coalkyl);
R and R are SH or SCO (Coalkyl);
R and Ra are OH:
R and Ra are heteroaryl;
X, Y, U, and V are Calkyl; and
X, Y, U, and V are each, independently, Cisalkyl; and
R, is absent.
Rs and R are absent.
In some embodiments, the compound is a compound of
In some embodiments, the compound is a compound of 50 Formula II, wherein:
Formula I, wherein:
R and R are SH or SCO (Coalkyl);
R and R are SH or SCOCH:
R and R are OH or N:
R and Ra are heteroaryl;
X,
Y, U, and V are Calkyl; and
X and Y are Calkyl
R, is absent.
55
U, and V are Calkyl; and
In some embodiments, the compound is a compound of
Rs and R are absent.
In some embodiments, the compound is a compound of Formula II, wherein:
R and R are SH or SCO (Coalkyl);
Formula I, wherein:
R and Ra are N:
R and R are SH or SCOCH:
X, Y, U, and V are Calkyl; and
60
R and Ra are imidazolyl,
R, is absent.
X and Y are Calkyl
In some embodiments, the compound is a compound of
U, and V are Calkyl; and
Formula II, wherein:
Rs and R are absent.
In some embodiments, the compound is a compound of
R and R are SH or SCO (Coalkyl);
65
Formula II, wherein:
R and Ra are N:
X, Y, U, and V are Csalkyl; and
RandR are SR;
R and Ra are heteroaryl;
R, is absent.
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In some embodiments, the compound is a compound of
Formula II, wherein:

R and R are SH or SCO (Coalkyl);
R and Ra are OH or N:
X, Y, U, and V are Csalkyl; and
R is absent.
In some embodiments, wherein the compound is a com
pound of Formula II, wherein:
R and R are SH or SCO (Coalkyl);
R and Ra are imidazolyl,
X, Y, U, and V are Calkyl; and
R is absent.
In some embodiments, the compound is a compound of

10

Formula II, wherein:

R and R are SH or SCO (Coalkyl);
R and Ra are imidazolyl:
X, Y, U, and V are Calkyl; and
R is absent.
In some embodiments, the compound is a compound of

15

Formula II, wherein:

R and R are SH or SCO Calkyl:
R and Ra are imidazolyl,
X and Y are each Calkyl;
U and V are each Calkyl; and
R is absent.
In some embodiments, at least one of R or R is C(O)R.

25

group.
30

In some embodiments, NR'R' is NH(Coalkyl).

In some embodiments, the NH(Coalkyl) is substituted
with a nitrilotriacetic acid.

At various places in the present specification Substituents
of compounds of the invention are disclosed in groups or in
ranges. It is specifically intended that the invention include
each and every individual subcombination of the members of
Such groups and ranges. For example, the term "Ce alkyl is
specifically intended to individually disclose methyl, ethyl,
Calkyl, Calkyl, Csalkyl, and Calkyl.
For compounds of the invention in which a variable
appears more than once, each variable can be a different
moiety selected from the Markush group defining the vari
able. For example, where a structure is described having two

35

tion.

As used herein, the term “alkyl is meant to refer to a
saturated hydrocarbon group which is straight-chained or
branched. Example alkyl groups include methyl (Me), ethyl
(Et), propyl (e.g., n-propyl and isopropyl), butyl (e.g., n-bu
tyl, isobutyl, t-butyl), pentyl (e.g., n-pentyl, isopentyl, neo
pentyl), and the like. An alkyl group can, for example, contain

40

As used herein, the term “alkynyl ether refers to an alky
nyl group or a cycloalkynyl group as defined herein, having at
least one oxygen incorporated into the alkyne chain. In some
embodiments alkynyl ether groups can have from 1-20 car
bon atoms.

45

As used herein, “aryl' refers to an aromatic carbocyclyl
group including monocyclic or polycyclic (e.g., having 2, 3 or
4 fused rings) aromatic hydrocarbons such as, for example,
phenyl, naphthyl, anthracenyl, phenanthrenyl, indanyl, inde
nyl, and the like. In some embodiments, aryl groups have
from 6 to about 20 carbon atoms.

50

55

60

from 1 to about 20, from 2 to about 20, from 1 to about 10,
from 1 to about 8, from 1 to about 6, from 1 to about 4, or from
1 to about 3 carbon atoms.

As used herein, “alkenyl refers to an alkyl group having
one or more double carbon-carbon bonds. Example alkenyl
groups include ethenyl, propenyl, cyclohexenyl, and the like.

As used herein, the term “alkyl ether refers to an alkyl
group or a cycloalkyl group as defined herein, having at least
one oxygen incorporated into the alkyl chain e.g., methyl
ethyl ether, diethyl ether, tetrahydrofuran. In some embodi
ments alkyl ether groups can have from 1-20 carbonatoms. In
some embodiments, the alkyl ether is a Copolyether group.
As used herein, the term “alkenyl ether refers to an alkenyl
group or a cycloalkenyl group as defined herein, having at
least one oxygen incorporated into the alkene chain. In some
embodiments alkenylether groups can have from 1-20 carbon
atOmS.

R" groups that are simultaneously present on the same com

pound; the two R groups can represent different moieties
selected from the Markush group defined for R. It is further
appreciated that certain features of the invention, which are,
for clarity, described in the context of separate embodiments,
can also be provided in combination in a single embodiment.
Conversely, various features of the invention which are, for
brevity, described in the context of a single embodiment, can
also be provided separately or in any Suitable Subcombina

3 to about 20, about 3 to about 10, or about 3 to about 7 carbon
atOmS.

In some embodiments, R, is NR'R''.
In some embodiments, NR'R' is a triazacyclononane

In some embodiments, the triazacyclononane group is Sub
stituted with an alkylcarboxylate.

8
As used herein, “alkynyl refers to an alkyl group having one
or more triple carbon-carbon bonds. Example alkynyl groups
include ethynyl, propynyl, and the like. As used herein,
"haloalkyl refers to an alkyl group having one or more halo
gen Substituents. Example haloalkyl groups include CF,
CFs, CHF, CC1, CHCl, CC1s, and the like. An alkyl
group in which all of the hydrogen atoms are replaced with
halogen atoms can be referred to as “perhaloalkyl.”
As used herein, “alkylene' or “alkylenyl refers to a bivalent
alkyl group. An example alkylene group is methylene or
ethylene.
As used herein, “alkenylene' or “alkenylenyl refers to a
bivalent alkenyl group. As used herein, 'carbocyclyl groups
are Saturated (i.e., containing no double or triple bonds) or
unsaturated (i.e., containing one or more double or triple
bonds) cyclic hydrocarbon moieties. Carbocyclyl groups can
be mono- or polycyclic (e.g., having 2, 3 or 4 fused rings) or
spirocyclic. Example carbocyclyl groups include cyclopro
pyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclo
pentenyl, 1.3-cyclopentadienyl, cyclohexenyl, norbornyl,
norpinyl, norcamyl, adamantyl, phenyl, and the like. Car
bocyclyl groups can be aromatic (e.g., “aryl') or non-aro
matic (e.g., “cycloalkyl). In some embodiments, carbocyclyl
groups can have from about 3 to about 30 carbonatoms, about

65

As used herein, "cycloalkyl refers to non-aromatic car
bocyclyl groups including cyclized alkyl, alkenyl, and alky
nyl groups. Cycloalkyl groups can include bi- or polycyclic
(e.g., having 2, 3 or 4 fused rings) ring systems as well as spiro
ring systems. Example cycloalkyl groups include cyclopro
pyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclo
pentenyl, cyclohexenyl, cyclohexadienyl, cycloheptatrienyl,
norbornyl, norpinyl, norcarnyl, adamantyl, and the like. Also
included in the definition of cycloalkyl are moieties that have
one or more aromatic rings fused (i.e., having a bond in
common with) to the cycloalkyl ring, for example, benzo
derivatives of pentane, pentene, hexane, and the like.
As used herein, "heterocyclyl or "heterocycle” refers to a
saturated or unsaturated carbocyclyl group wherein one or
more of the ring-forming carbon atoms of the carbocyclyl
group is replaced by a heteroatom such as O, S, or N. Hetero
cyclyl groups can be aromatic (e.g., "heteroaryl') or non
aromatic (e.g., "heterocycloalkyl). Heterocyclyl groups can
also correspond to hydrogenated and partially hydrogenated
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heteroaryl groups. Heterocyclyl groups can be characterized
as having 3-14 ring-forming atoms. In some embodiments,
heterocyclyl groups can contain, in addition to at least one

10
benzimidazolyl, indolinyl, and the like. In some embodi
ments, the heteroaryl group has from 1 to about 20 carbon

heteroatom, from about 1 to about 20, about 2 to about 10, or

carbon atoms. In some embodiments, the heteroaryl group
contains 3 to about 14, 3 to about 7, or 5 to 6 ring-forming
atoms. In some embodiments, the heteroaryl group has 1 to

atoms, and in further embodiments from about 3 to about 20

about 2 to about 7 carbon atoms and can be attached through
a carbon atom or heteroatom. In further embodiments, the

heteroatom can be oxidized (e.g., have an OXO or Sulfindo
Substituent) or a nitrogenatom can be quaternized. Examples
of heterocyclyl groups include morpholino, thiomorpholino,
piperazinyl, tetrahydrofuranyl, tetrahydrothienyl, 2,3-dihy
drobenzofuryl, 1,3-benzodioxole, benzo-1,4-dioxane, pip
eridinyl, pyrrolidinyl, isoxazolidinyl, isothiazolidinyl, pyra
Zolidinyl, oxazolidinyl, thiazolidinyl, imidazolidinyl, and the
like, as well as any of the groups listed below for "heteroaryl
and "heterocycloalkyl.” Further example heterocycles
include pyrimidinyl, phenanthridinyl, phenanthrolinyl,
phenazinyl, phenothiazinyl, phenoxathiinyl, phenoxazinyl,
phthalazinyl, piperazinyl, piperidinyl. 3,6-dihydropyridyl,
1.2.3,6-tetrahydropyridyl, 1,2,5,6-tetrahydropyridyl, piperi
donyl, 4-piperidonyl, piperonyl, pteridinyl, purinyl, pyranyl.
pyrazinyl, pyrazolidinyl, pyrazolinyl, pyrazolyl pyridazinyl,
pyridooxazole, pyridoimidazole, pyridothiazole, pyridinyl,
pyridyl, pyrimidinyl, pyrrolidinyl, pyrrolinyl, 2H-pyrrolyl,
pyrrolyl, tetrahydrofuranyl, tetrahydroisoquinolinyl, tetrahy
droquinolinyl, tetrazolyl, 6H-1,2,5-thia-diazinyl, 1,2,3-thia
diazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadia
Zolyl, thianthrenyl, thiazolyl, thienyl, thienothiazolyl,
thienooxazolyl, thienoimidazolyl, thiophenyl, triazinyl, 1.2,
3-triazolyl, 1,2,4-triazolyl, 1,2,5-triazolyl, 1,3,4-triazolyl,
Xanthenyl, octahydro-isoquinolinyl, oxadiazolyl, 1.2.3-oxa
diazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadia
Zolyl, oxazolidinyl, oxazolyl, oxazolidinyl, quinazolinyl,
quinolinyl, 4H-quinolizinyl, quinoxalinyl, quinuclidinyl,
acridinyl, azocinyl, benzimidazolyl, benzofuranyl, ben
Zothiofuranyl, benzo-thiophenyl, benzoxazolyl, benzthiaz
olyl, benztriazolyl, benztetrazolyl, benzisoxazolyl, ben
Zisothiazolyl, benzimidazolinyl, methylenedioxyphenyl,
morpholinyl, naphthyridinyl, deca-hydroquinolinyl, 2H.6H
1.5.2dithiazinyl, dihydrofuro2.3-btetrahydrofuran, furanyl,
furazanyl, carbazolyl, 4aH-carbazolyl, carbolinyl, chroma
nyl, chromenyl, cinnolinyl, imidazolidinyl, imidazolinyl,
imidazolyl, 1H-indazolyl, indolenyl, indolinyl, indolizinyl,
indolyl, 3H-indolyl, isobenzofuranyl, isochromanyl, isolinda
Zolyl, isoindolinyl, isoindolyl, isoquinolinyl, isothiazolyland
isoxazolyl. Further examples of heterocycles include azeti
din-1-yl, 2,5-dihydro-1H-pyrrol-1-yl, piperindin-1yl, piper
azin-1-yl, pyrrolidin-1-yl, isoquinol-2-yl, pyridin-1-yl, 3.6dihydropyridin-1-yl, 2,3-dihydroindol-1-yl,
13,49
tetrahydrocarbolin -2-yl, thieno2.3-cpyridin-6-y1, 3,4,10.
10a-tetrahydro-1H-pyrazino 1,2-alindol-2-yl, 1.2.4.4a.5,6hexahydro-pyrazino 1,2-aquinolin-3-yl pyrazino 1.2-a
quinolin-3-yl, diazepan-1-yl, 1,4,5,6-tetrahydro-2H-benzo
fisoquinolin-3-yl, 1.4.4a.5,6,10b-hexahydro-2H-benzof
isoquinolin-3-yl, 3.3a,8.8a-tetrahydro-1H-2-aza-cyclopenta
alinden-2-yl, and 2.3.4.7-tetrahydro-1H -azepin-1-yl,
aZepan-1-yl. Also included are fused ring and spiro com
pounds containing, for example, the above heterocycles.
As used herein, "heteroaryl groups are aromatic hetero
cyclyl groups and include monocyclic and polycyclic (e.g.,
having 2, 3 or 4 fused rings) aromatic hydrocarbons that have
at least one heteroatom ring member Such as Sulfur, oxygen,
or nitrogen. Heteroaryl groups include, without limitation,
pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl, furyl,
quinolyl, isoquinolyl, thienyl, imidazolyl, thiazolyl, indolyl,
pyrryl, oxazolyl, benzofuryl, benzothienyl, benzthiazolyl,
isoxazolyl pyrazolyl, triazolyl, tetrazolyl, indazolyl, 1,2,4thiadiazolyl, isothiazolyl, benzothienyl, purinyl, carbazolyl,

about 4, 1 to about 3, or 1 to 2 heteroatoms.
10

15

As used herein, "heterocycloalkyl refers to non-aromatic
heterocyclyl groups including cyclized alkyl, alkenyl, and
alkynyl groups where one or more of the ring-forming carbon
atoms is replaced by a heteroatom such as an O, N, or Satom.
Example heterocycloalkyl groups include morpholino, thio
morpholino, piperazinyl, tetrahydrofuranyl, tetrahydrothie
nyl, 2,3-dihydrobenzofuryl, 1,3-benzodioxole, benzo-1,4-di
OXane,

piperidinyl,

pyrrolidinyl,

isoxazolidinyl,

isothiazolidinyl, pyrazolidinyl, oxazolidinyl, thiazolidinyl,
imidazolidinyl, and the like. Also included in the definition of
heterocycloalkyl are moieties that have one or more aromatic
rings fused (i.e., having a bond in common with) to the non
aromatic heterocyclic ring, for example phthalimidyl, naph
thalimidyl, and benzo derivatives of heterocycles such as
indolene and isoindolene groups. In some embodiments, the
heterocycloalkyl group has from 1 to about 20 carbon atoms,
and in further embodiments from about 3 to about 20 carbon
25

atoms. In some embodiments, the heterocycloalkyl group
contains 3 to about 14, 3 to about 7, or 5 to 6 ring-forming
atoms. In some embodiments, the heterocycloalkyl group has
1 to about 4, 1 to about 3, or 1 to 2 heteroatoms. In some

30

35

40

embodiments, the heterocycloalkyl group contains 0 to 3
double bonds. In some embodiments, the heterocycloalkyl
group contains 0 to 2 triple bonds.
As used herein, "halo” or “halogen' includes fluoro,
chloro, bromo, and iodo. As used herein, “alkoxy' refers to an
—O-alkyl group. Example alkoxy groups include methoxy,
ethoxy, propoxy (e.g., n-propoxy and isopropoxy), t-butoxy,
and the like. As used herein, “aryloxy' refers to an —O-aryl
group. An example aryloxy group is phenoxy. As used here,
"haloalkoxy' refers to an —O-haloalkyl group. An example
haloalkoxy group is OCF3. As used herein, “carbocyclyla
lkyl refers to an alkyl moiety substituted by a carbocyclyl
group.

45

50
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Example carbocyclylalkyl groups include “aralkyl (alkyl
substituted by aryl (“arylalkyl)) and “cycloalkylalkyl (alkyl
Substituted by cycloalkyl). In some embodiments, carbocy
clylalkyl groups have from 4 to 24 carbon atoms.
As used herein, "heterocyclylalkyl refers to an alkyl moi
ety substituted by a heterocarbocyclyl group. Example het
erocarbocyclylalkyl groups include “heteroarylalkyl (alkyl
substituted by heteroaryl) and "heterocycloalkylalkyl (alkyl
substituted by heterocycloalkyl). In some embodiments, het
erocyclylalkyl groups have from 3 to 24 carbon atoms in
addition to at least one ring-forming heteroatom.
As used herein, “amino” refers to an NH group. “Alky
lamino” refers to an amino group Substituted by an alkyl
group and “dialkylamino” refers to an amino group Substi
tuted by two alkyl groups.
As used herein, “aminocarbonyl refers to CONH2.
As used herein, “alkylaminocarbonyl refers to CONH
(alkyl).
As used herein, “alkylaminocarbonyl refers to CON
(alkyl).
As used herein, “carboxy” or “carboxyl refers to COOH.
As used herein, "carboxyalkyl ester” refers to COO-alkyl.
As used herein, “carboxyaryl ester” refers to COO-aryl.
As used herein, “hydroxy' refers to OH.
As used herein, “mercapto' refers to SH.
As used herein, “sulfinyl refers to SO.
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As used herein, “sulfonyl refers to SO.
As used herein, “aminosulfonyl refers to SONH2.
As used herein, “alkylaminosulfonyl refers to SONH
(alkyl).
As used herein, “dialkylaminosulfonyl refers to SON
(alkyl).
As used herein, “arylsulfonyl refers to SO-aryl.
As used herein, “arylsulfinyl refers to SO-aryl.
As used herein, “alkylsulfonyl” refers to SO-alkyl.
As used herein, “alkylsulfinyl refers to SO-alkyl.
Unless otherwise indicated, the compounds provided in the
above formula are meant to include salts, enantiomers, dias

tereomers, racemic mixtures, crystalline forms, non-crystal
line forms, amorphous forms, hydrates and Solvates thereof.
When compounds of the present invention contain rela
tively basic functionalities, acid addition salts can be obtained
by contacting the neutral form of Such compounds with a

12
In some embodiments, the compounds of Formula I are
selected from:
(Z)-3,4-bis(8-mercaptooctyl)hex-3-ene-1,6-diol;
(Z)-(9,10-bis(2-hydroxyethyl)octadec-9-ene-1,18-diyl)
diethanethioate;

10

18-dithiol; and
15

forms, such as keto-enol tautomers. Tautomeric forms can be

25

30

35

2,2'-(4,5-bis(6-mercaptohexyl)-1,2-phenylene)diethanol:
((4.5-bis(2-hydroxyethyl)-1,2-phenylene)bis(hexane-6,1diyl))diethanethioate:
5.5'-(4,5-bis(6-mercaptohexyl)-1,2-phenylene)bis(pen
tan-1-ol);
((4.5-bis(5-hydroxypentyl)-1,2-phenylene)bis(hexane-6,
1-diyl))diethanethioate:
8.8'-(4,5-bis(2-(1H-imidazol-1-yl)ethyl)-1,2-phenylene)
bis(octane-1-thiol);
((4.5-bis(2-(1H-imidazol-1-yl)ethyl)-1,2-phenylene)bis
(octane-8,1-diyl))diethanethioate:
6,6'-(4,5-diheptyl-1,2-phenylene)bis(hexan-1-ol);
6,6'-(4,5-bis(pyridin-2-ylethynyl)-1,2-phenylene)bis(hex
5-yne-1-thiol):
((4.5-bis(pyridin-2-ylethynyl)-1,2-phenylene)bis(hex-5yne-6,1-diyl))diethanethioate:
4,4'-(4,5-bis(4-mercaptobutyl)-1,2-phenylene)bis(butan
1-ol):
((4.5-bis(4-hydroxybutyl)-1,2-phenylene)bis(butane-4,1diyl))diethanethioate:
2-(2-(2-azidoethyl)-4,5-bis(6-mercaptohexyl)phenyl)
ethanol:

40

45

50

55

in equilibrium or sterically locked into one form by appropri
ate Substitution.

Some of the compounds of the invention can exist in unsol
vated forms as well as Solvated forms, including hydrated
forms. In general, the Solvated forms are equivalent to unsol
vated forms and are intended to be encompassed within the
Scope of the present invention. Certain compounds of the
present invention may exist in multiple crystalline or amor
phous forms. In general, all physical forms are equivalent for
the uses contemplated by the present invention and are
intended to be within the scope of the present invention.

(Z) 9,10-bis(2-(1H-imidazol-1-yl)ethyl)octadec-9-ene-1,
18-diyl)diethanethioate.
In some embodiments, the compounds of Formula II are

selected from:

sufficient amount of the desired acid, either neat or in a

suitable inert solvent. Examples of acceptable acid addition
salts include those derived from inorganic acids like hydro
chloric, hydrobromic, nitric, carbonic, phosphoric, partially
neutralized phosphoric acids, Sulfuric, partially neutralized
Sulfuric, hydroiodic, or phosphorous acids and the like, as
well as the salts derived from organic acids like acetic, pro
pionic, isobutyric, maleic, malonic, benzoic, succinic,
Suberic, fumaric, mandelic, phthalic, benzenesulfonic,
p-tolylsulfonic, citric, tartaric, methanesulfonic, and the like.
Also included are salts of amino acids such as arginate and the
like, and salts of organic acids like glucuronic or galactunoric
acids and the like. Certain specific compounds of the present
invention may contain both basic and acidic functionalities
that allow the compounds to be converted into either base or
acid addition salts. The neutral forms of the compounds of the
present invention may be regenerated by contacting the salt
with a base or acid and isolating the parent compound in the
conventional manner. The parent form of the compound dif
fers from the various salt forms in certain physical properties,
such as solubility in polar solvents, but otherwise the salts are
equivalent to the parent form of the compound for the pur
poses of the present invention.
As noted above, some of the compounds of the present
invention possess chiral or asymmetric carbonatoms (optical
centers) or double bonds; the racemates, diastereomers, geo
metric isomers and individual optical isomers are all intended
to be encompassed within the scope of the present invention.
Compounds of the invention can also include all isotopes
of atoms occurring in the intermediates or final compounds.
Isotopes include those atoms having the same atomic number
but different mass numbers. For example, isotopes of hydro
gen include tritium and deuterium.
Compounds of the invention can also include tautomeric

(3R,4S)-3,4-bis(8-mercaptooctyl)hexane-1,6-diol;
((9R,10S)-9,10-bis(2-hydroxyethyl)octadecane-1,18
diyl)diethanethioate:
(3R,4R)-3,4-bis(8-mercaptooctyl)hexane-1,6-diol;
((9R,10R)-9,10-bis(2-hydroxyethyl)octadecane-1,18
diyl)diethanethioate:
(Z)-9,10-bis(2-(1H-imidazol-1-yl)ethyl)octadec-9-ene-1,

((4-(2-azidoethyl)-5-(2-hydroxyethyl)-1,2-phenylene)bis
(hexane-6,1-diyl))diethanethioate:
6,6'-(4,5-bis(2-azidoethyl)-1,2-phenylene)bis(hexane-1thiol):
((4.5-bis(2-azidoethyl)-1,2-phenylene)bis(hexane-6,1diyl))diethanethioate:
5.5'-(4,5-bis(5-azidopentyl)-1,2-phenylene)bis(pentane
1-thiol);
((4.5-bis(5-azidopentyl)-1,2-phenylene)bis(pentane-5,1diyl))diethanethioate:
5-(2-(5-azidopentyl)-4,5-bis(5-mercaptopentyl)phenyl)
pentan-1-ol;
((4-(5-azidopentyl)-5-(5-hydroxypentyl)-1,2-phenylene)
bis(pentane-5,1-diyl)) diethanethioate:
4,4'-(4,5-bis(4-(1H-imidazol-1-yl)butyl)-1,2-phenylene)
bis(butane-1-thiol):
((4.5-bis(4-(1H-imidazol-1-yl)butyl)-1,2-phenylene)bis
(butane-4,1-diyl))diethanethioate:
2,2'-(4,5-bis(6-(1H-imidazol-1-yl)hexyl)-1,2-phenylene)
diethanethiol:

60

65

((4.5-bis(6-(1H-imidazol-1-yl)hexyl)-1,2-phenylene)bis
(ethane-2,1-diyl))diethanethioate:
5.5'-(4,5-bis(5-mercaptopentyl)-1,2-phenylene)bis(pen
tan-1-ol);
((4.5-bis(5-hydroxypentyl)-1,2-phenylene)bis(pentane-5,
1-diyl))diethanethioate:
6,6'-(4,5-bis(2-(1H-imidazol-1-yl)ethyl)-1,2-phenylene)
bis(hexane-1-thiol); and

US 9,079,835 B2
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conditions can be determined by one skilled in the art by
routine optimization procedures.
The processes described herein can be monitored accord
ing to any Suitable method known in the art. For example,
product formation can be monitored by spectroscopic means,

13
((4.5-bis(2-(1H-imidazol-1-yl)ethyl)-1,2-phenylene)bis
(hexane-6,1-diyl))diethanethioate.
In some embodiments of the invention, the compounds of
the invention comprise:
1-(11-mercaptoundecyl)imidazole
(Z)-9,10-bis(2-(1H-imidazol-1-yl)ethyl)octadec-9-ene-1,

such as nuclear magnetic resonance spectroscopy (e.g., "Hor
'C), infrared spectroscopy, spectrophotometry (e.g., UV

18-dithiol:

(Z)(9,10-bis(2-(1H-imidazol-1-yl)ethyl)octadec-9-ene-1,
18-diyl)diethanethioate
6,6'-(4,5-bis(2-(1H-imidazol-1-yl)ethyl)-1,2-phenylene)
bis(hexane-1-thiol); and
((4.5-bis(2-(1H-imidazol-1-yl)ethyl)-1,2-phenylene)bis
(hexane-6,1-diyl)).
As noted above, some of the compounds of the present
invention possess chiral or asymmetric carbonatoms (optical
centers) or double bonds; the racemates, diastereomers, geo
metric isomers and individual optical isomers are all intended
to be encompassed within the scope of the present invention.
The compounds of Formula I and II have unique structural
features that are useful for several applications. In particular,
the inventive compounds contain two amphiphile chains that
are joined by a non-polar linker comprising a carbon-carbon
single, double or arene bond. This allows for highly organized
and uniform binding of the amphiphile chains to a Surface for
the formation of self-ssembled monolayers. The compounds
of Formula I and II are believed to provide enhanced stability
in monolayer structures compared to single-chain
amphiphiles due to cooperative multivalent bonding of two
amphiphile chains. The inventive compounds are also

10
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out in one solvent or a mixture of more than one solvent.
30

believed to adsorb onto metal surfaces at an enhanced rate

with high packing density fostered by the cross-linking
present in the structures. Upon packing into a monolayer or
similar aggregate, the two chains of the cross-linked
amphiphile are in close proximity. Varying the functionality

35

on each chain allows construction of functionalized surfaces

with an exceptional degree of lateral control.
It has been discovered by Applicants that the structural and
functional properties of the monolayer can be modulated by
adjusting the linker groups and amphiphile chains of selected
amphiphile compounds. For example, the rigidity of the
monolayers can be controlled by changing the linker moiety
(carbon-carbon single, double or arene bond-linker) and by
adjusting the relative position of the crosslinker along the
amphiphile chain. A vast array of functional groups may be
appended at any point along the amphiphile chain to achieve
absolute and independent control over the functionality on
each segment. The cross-linking of the two amphiphile chains
can be conducted at any location along the amphiphile to
fine-tune the flexibility or rigidity at either end of the mol
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ecule.

Synthesis
The novel compounds of the present invention can be pre
pared in a variety of ways known to one skilled in the art of
organic synthesis. The compounds of the present invention
can be synthesized using the methods as hereinafter described
below, together with synthetic methods known in the art of
synthetic organic chemistry or variations thereon as appreci
ated by those skilled in the art.
The compounds of this invention can be prepared from
readily available starting materials using the following gen
eral methods and procedures. It will be appreciated that where
typical or preferred process conditions (i.e., reaction tem
peratures, times, mole ratios of reactants, solvents, pressures,
etc.) are given, other process conditions can also be used
unless otherwise stated. Opimum reaction conditions may
vary with the particular reactants or solvent used, but Such

visible), or mass spectrometry, or by chromatography Such as
high performance liquid chromatograpy (HPLC) or thin layer
chromatography.
Preparation of compounds can involve the protection and
deprotection of various chemical groups. The need for pro
tection and deprotection, and the selection of appropriate
protecting groups can be readily determined by one skilled in
the art. The chemistry of protecting groups can be found, for
example, in Green, et al., Protective Groups in Organic Syn
thesis, 2d. Ed., Wiley & Sons, 1991, which is incorporated
herein by reference in its entirety.
The reactions of the processes described herein can be
carried out in suitable solvents which can be readily selected
by one of skill in the art of organic synthesis. Suitable solvents
can be substantially nonreactive with the starting materials
(reactants), the intermediates, or products at the temperatures
at which the reactions are carried out, i.e., temperatures which
can range from the solvents freezing temperature to the
Solvents boiling temperature. A given reaction can be carried
Depending on the particular reaction step, Suitable solvents
for a particular reaction step can be selected.
The novel compounds of this invention may be prepared
using the reaction pathways and techniques as described
below.

A series of compounds of formula 12 are prepared by the
methods outlined in scheme 1 (where n of formulas 5-12 and
m of formulas 7-12 correspond to appropriate values that
would afford compounds of the invention). 1,2-dimethoxy
benzene is treated with HIO and I in methanol to afford
compound 2, which is reacted BBr to provide 3. The diol is
then treated with Tf.C) in pyridine to provide the correspond
ing triflate, which is alkylated with 5 to form product 6.
Alkylation of 6 is accomplished by treating with compound 7
to provide product 8. The alkyne and benzyl groups of 8 are
removed by hydrogenation to provide compound 9. The
resulting diol is treated with MsCl to form 10, which is then
thiylated upon treatment with potassium thioacetate to afford
product 11. The acetyl groups are removed with DIBAL-H to
produce the final compound 12.
Scheme 1
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A series of compounds of formula 24 are prepared by the
methods outlined in scheme 3 (where m of formulas 18-24
corresponds to appropriate values that would afford com
pounds of the invention). An alkynol is protected as the THP
ether followed by lithiation and homologation of the terminal
alkyne with methyl chloroformate to afford compound 19.
Conjugate addition of an in situ prepared Stannylcuprate to
the enoate affords vinyl Stannane compound 20, which under
goes Cu(I)-mediated homocoupling to give bis enoate com
pound 21. Reductive deconjugation under dissolving metal
conditions affords compound 22 as a mixture of isomers.
Removal of the THP protecting groups and activation as the
methanesulfonate gives compound 23. Displacement of the
sulfonate groups with KSAc and global reduction with
DIBAl-H provides the final compound 24.
Scheme 3
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A series of compounds of formula 17 are prepared by the
methods outlined in scheme 2 (where m of formulas 13-17
corresponds to appropriate values that would afford com
pounds of the invention). An alkeneol 13 is treated with PPh

1) LDA, BuSnH
COMe -e2) CuCn, MeOH

THPO(H2C)
50
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THF

SnBus

and N-chlorosuccinimide in THF to afford chloride 14, which

undergoes cross-metathesis in the presence of Grubbs 2"
generation catalyst and methylacrylate to provide 15. The
enoate is then reductively dimerized in the presence of SmI
to form product 16 as a mixture of stereoisomers. Displace
ment of the chlorides with KSAc and global reduction with
DIBAl-Haffords the final compound 17.

THPO,(HCy1 S
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multivalent cation. In some embodiments, at least about 5%
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metal and semiconductor Surfaces which can be used to fab
ricate electrochemical biosensors.

The term “self-assembled monolayer” (SAM), as used
herein, refers to a relatively ordered assembly of molecules
(including compounds of Formula I or II) adsorbed on a
Surface, in which the molecules are oriented approximately
parallel to each other and roughly perpendicular to the Sur
face. Each of the molecules preferably includes a functional
group that adheres to the Surface, and a portion that interacts
with neighboring molecules in the monolayer to form the
relatively ordered array. Preferably, all of the species that
participate in the SAM include a functionality that binds,
optionally covalently, to the surface, such as a thiol which will
bind covalently to a metal. Such as gold, Surface. A self
assembled monolayer on a Surface, in accordance with the
invention, can be composed of a mixture of species (e.g. thiol
species when gold is the Surface) that can present (expose)
essentially any chemical or biological functionality. For
example, they can include species terminating in a binding
partner of an affinity tag, e.g. terminating in a chelate that can
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40, 45, or 50% of the compounds are functionalized with a
moiety that is capable of binding a monovalent cation.
In some embodiments, the SAM-functionalized moiety
capable of binding a multivalent cation is a chelating mol
ecule. By the term “chelating molecule' or “chelating agent'
is meant a compound that has the ability to bond to a metalion
through two or more atoms of the chelating agent to form a
complex or a reaction product. The bonds may be covalent or
ionic or a combination thereof. Examples of suitable chelat
ing agents include acidic materials such as ethylenediamine
tetraacetic acid, nitrilo triacetic acid and Sodium tripolyphos
phate. Other Suitable chelating agents of the invention
include, but are not limited to, chelating agents comprising
nitrilotriacetic acid (NT A), 1,4,7-triazacyclononane
(TACN), diethylene triamine pentaacetic acid (DTPA), 14.7,
10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA),
or imidazole moieties. Other Suitable chelating agents
include, but are not limited to N,N'-di-L-histidylethane-1,2diamine (Dhen), iminodiacetic acid (IDA), tris(carboxymeth
yl)ethylenediamine (TED) carboxymethylated aspartic acid
(CM-Asp), dipicolylamine (DPA), aminohydroxamine acid,
salicylaldehyde, or ortho-phosphoserine (OPS).
In some embodiments of the invention, a multivalent cation

50

is attached to the monolayer upon binding to the SAM-func
tionalized moiety, described above, that is capable of binding
a multivalent cation. As used herein, the term “multivalent

coordinate a metal Such as nitrilotriacetic acid which, when in

complex with nickel atoms, captures a metal binding tagged
species such as a histidine-tagged binding species.

of the compounds are functionalized with a moiety that is
capable of binding a monovalent cation. In other embodi
ments, at least about 1-5% or about 5-10% or about 20, 30,35,

Methods

The compounds described herein are ideally suited for
several applications, including biomaterial fabrication, cor
rosion resistance, lithographic patterning and microelectron
ics fabrication. This new class of compounds can also be used
to create highly stable self-assembled monolayers (SAMs) on

18
As used herein, the word "comprise or variations such as
“comprises” or “comprising,” will be understood to imply the
inclusion of a stated element or group of elements, but not to
the exclusion of any other element or group of elements.
As used herein, a “biomolecule' is any molecule of a type
typically foundina biological system, whether Such molecule
is naturally occurring or the result of Some external distur
bance of the system (e.g., a disease, poisoning, genetic
manipulation, etc.), as well as synthetic analogs and deriva
tives thereof. Non-limiting examples of biomolecules include
amino acids (naturally occurring or synthetic), peptides,
polypeptides, glycosylated and unglycosylated proteins (e.g.,
polyclonal and monoclonal antibodies, receptors, interferons,
enzymes, etc.), nucleosides, nucleotides, oligonucleotides
(e.g., DNA, RNA, PNA oligos), polynucleotides (e.g., DNA,
cDNA, RNA, etc.), carbohydrates, hormones, haptens, ste
roids, toxins, etc. Biomolecules may be isolated from natural
Sources, or they may be synthetic.
In some embodiments, the self-assembled monolayer of
the invention is composed of a plurality of compounds of
Formula I or II, whereby a portion of the compounds are
functionalized with a moiety that is capable of binding a

55

cation.” refers to materials capable of carryingapositive ionic
charge of +2 or greater. In some embodiments, the multivalent
cation is a divalent or trivalent cation. Nonlimiting examples

In some embodiments of the invention, the self-assembled

of "multivalent cationic' materials include alkaline earth

monolayers can be used in a sensor to detect biomolecules in
a sample. For example, in one embodiment, one or more
biomolecules in a sample, can be detected by (a) providing a
component that comprises a self-assembled monolayer com
prising a compound of Formula I or II; (b) binding a multi
Valent cation to the monolayer; (c) capturing a binding partner
onto the monolayer, wherein the binding partner comprises a
detectable marker and a moiety capable of binding the mul
tivalent cation; (d) exposing the sample to the monolayer
component; and (e) detecting a signal from the detectable

metal ions, aluminum ions and heavy metal ions. In some

marker.

embodiments of the invention, the multivalent cation is
nickel, cobalt, or zinc. In some embodiments, the multivalent
60

65

cation is Zn(II), Co(II)), or Ni(II). In other embodiments of
the invention, the multivalent cation is Fe(III), Cu(II), V(III),
W(IV), Ca(II), Al(III) or Yb(III).
In some embodiments of the invention, a binding partner is
captured onto the monolayer, the binding partner comprising
a detectable marker and a moiety capable of binding a mul
tivalent cation. As used herein, term “binding or “bound
refers to the interaction between a corresponding pair of

US 9,079,835 B2
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molecules that exhibit mutual affinity or binding capacity,
typically specific or non-specific binding or interaction,
including biochemical, physiological, and/or pharmaceutical
interactions. Biological binding defines a type of interaction
that occurs between pairs of molecules including proteins,
nucleic acids, glycoproteins, carbohydrates, hormones and
the like. Specific examples include antibody/antigen, anti
body/hapten, enzyme? substrate, enzyme/inhibitor, enzyme?
cofactor, binding protein/substrate, carrier protein/substrate,
lectin/carbohydrate, receptor/hormone, receptor/effector,
complementary strands of nucleic acid, protein/nucleic acid
repressor/inducer, ligand/cell Surface receptor, virus/ligand,

20
state. The change in redox state can be measured spectropho
tometrically. Non-limiting examples of suitable redox mol
ecules include redox indicators such as thionine, brilliant

10

etc.

Accordingly, as used, herein, a “binding partner” refers to
a molecule that can undergo the aforementioned binding with
a particular molecule. Biological binding partners are
examples. For example, the protein Arah2 (or a peptide
epitope therefrom) is a binding partner of anti-peanut anti
body IgY, and vica versa. Accordingly, in Some embodiments
of the invention, the binding partner is a biological binding
partner. Suitable binding partners include, for example, pep
tides, proteins, nucleic acids, glycoproteins, lipids, carbohy

15

drates, hormones and the like. In some embodiments of the

invention, the binding partner is a peptide, protein or nucleic
acid. In one embodiment, the binding partner is a peptide.
As used herein, a "peptide' is an oligomer in which the
monomers are amino acids and which is joined with another
peptide through amide bonds, and is alternatively referred to
as a polypeptide. Peptides comprise at least two amino acids,
and are usually, but not exclusively, less than 50 amino acids
in length. According to the invention, the peptide probes
described herein may be partially or fully synthetic, and may,
for example, comprise one or more of the following moieties:
cyclized residues or peptides, multimers of peptides, labels,
and/or other chemical moieties. The peptide probes of the
invention described herein may interact with, but are not
limited to, antibodies, or antigens such as specific proteins,
nucleic acids, lipids, or polysaccharides. In some embodi
ments, the peptide probes are generally specific for the target
biomolecule to be detected. These peptides can be used as
probes for antigens detection when the use of specific anti
bodies is not necessary.
According to the invention, the binding partner is labeled
with a detectable marker directly or indirectly, so that the
binding partner-biomolecule complex can be detected.
According to the invention, a “detectable marker' is not
restricted to a special type of detection marker, Such as bio
chemical detection marker, but includes any residue known in

25
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more histidine amino acids. In other embodiments of the
35
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some embodiments of the invention, the detectable marker is
a redox molecule. The term “redox molecule.” “redox indi

cator,” or “redox dye denotes a molecule which is capable of
accepting or donating an electron thereby changing its redox

tripolyphosphate. Other Suitable chelating agents of the
invention include, but are not limited to, chelating agents
comprising nitrilotriacetic acid (NT A), 1,4,7-triazacy
clononane (TACN), diethylene triamine pentaacetic acid
(DTPA), 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraace
tic acid (DOTA), or imidazole moieties.
In some embodiments, the SAM contains thiolated mol

45

ecules that are adsorbed to a metal surface via a thiol-metal

bond. In this embodiment, the metal Surface can include a

gold surface. The sulfur/gold interaction is very stable and
allows for the preparation of SAMs containing thiol func
tional groups even in the presence of a variety of other Sub
50

stituents. In some embodiments of the invention, the SAM

can be formed on metal, metal alloy, or semiconductors Sur
faces, including Pt, Cu, Pd, Ni, Ir, Ru, Ag, Hg, Zn, Ge. HgTe,
AgS, AuAg, AuCu, CdS, FePt, GaAs, InP, PbS, PdAg., ZnSe,

radioactive marker, or a redox-active marker. In some
embodiments, the detectable marker includes, but is not lim

ited to, a His-tag (detectable through its affinity to anti-His
antibodies or with fluorescent probes bearing metal ions),
glutathione transferase (GST) (detectable through its high
affinity for glutathione), Flag-tag (detectable using antibodies
against the flag sequence: N-DYKDDDDK-C), biotin (de
tectable with anti-biotin antibodies or avidin/strepavidine
tagged detection strategies such as horseradish peroxidase,
alkaline phosphatase or fluorescent probes), Ha-tag (detect
ably through its affinity for anti-HA antibody), and Myc-tag
(detectable with an antibody against the Myc epitope). In

invention, the chelating agent is a histidine (His) tag such as
a hexahistidine moiety. In other embodiments of the inven
tion, the chelating agent include compounds such as ethyl
enediamine tetraacetic acid, nitrilo triacetic acid and sodium

the art which is suitable for detection. In some embodiments

of the present invention, the binding partner defined above
comprises a detectable marker that is a fluorescent marker,

cresyl blue, methylene blue (3.7-bis(Dimethylamino) -phe
nothiazin-5-ium chloride) and benzyl viologen. Other suit
able redox molecules include, for example, alizarin brilliant
blue, 2,6-dichlorophenolindophenol, gallocyanine, new
methylene blue, N,N-dimethyl-disulphonated thionine,
phenazine ethoSulphate, resorufin, Safrainine-O, phenothiazi
none, toluidine blue-O, nile blue, ferrocene, anthraquinone,
Ru(bpy), Os(bpy), Co(bpy), thidiaZuron (TDZ), 6-benzy
laminopurine, and derivatives thereof. In one embodiment of
the invention, the redox indicator is methylene blue.
According to the invention, at least one target biomolecule
in a specimen can be quantified by counting the signals of the
detectable marker directly or indirectly. When the labeled
marker is a redox molecule, dye, fluorophore or radioisotope,
the presence of the biomolecule can be quantified directly by
counting the signal of the marker.
In Some embodiments, the binding partner is also function
alized with a moiety capable of binding multivalent cations.
In this embodiment, the moiety capable of binding a multi
Valent cation includes chelating molecules. Here, the term
“chelating molecule' or “chelating agent' includes any com
pound that has the ability to bond to a metal ion through two
or more atoms of the chelating agent to form a complex or a
reaction product. The bonds may be covalent or ionic or a
combination thereof. In some embodiments, the chelating
agent comprises one or more amino acids. For example, in
some embodiments, the chelating agent can comprise one or

ZnS, CdSe, and stainless steel surfaces. Suitable surfaces are
55

described in Chemical Reviews, 2005, 105(4) 1107, which is
incorporated by reference herein in its entirety.
In some embodiments, the SAM contains at least one sil
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anol functional group (or a precursor Such as an alkoxysilane
that readily liberates a silanol upon exposure to moisture) that
is capable of forming a covalent linkage to a siloxane or
similar Surface. The SAM can be appended using silane group
with a wide range of Substrates, including silicon-based mate
rials (e.g., silicon wafers, silicon nanowires), diamond-based
materials (e.g., boron-doped diamond Substrates), borosili
cate and quartz. Substrates, transparent conducting electrode
materials (e.g., indium tin oxide), and carbon-based materials
(e.g., glassy carbon, carbon nanotubes). In some embodi
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ments, the SAM contains at least one basic nitrogen in the
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Example 1

form of an amine, imidazole, triazole, or the like, that can be

5,5'-(4,5-bis(5-mercaptopentyl)-1,2-phenylene)bis
(pentan-1-ol)

absorbed to a metal surface.

In some embodiments, a SAM is prepared by adsorbing the
compound of Formula I or II onto a metal Surface. A surface
bound SAM containing a terminal reactive group (Such as a
chelating agent) can be used as platform onto which one can
couple different peptide probes to the monolayer.
In some embodiments, the monolayer can be formed by
adsorbing a compound of Formula I or II, functionalized with
a chelating agent (Such as imidazole), onto a gold disk elec
trode, followed by Subsequent adsorption of a passivating
diluent, such as 8-mercapto-1-octanol (C8-OH). The mixed
monolayer is then exposed to metal ions for direct coordina
tion with the surface-immobilized imidazole ligands. Various
cations are known to coordinate with imidazole ligands. Such
as metal ions Zinc (Zn(II)), cobalt (Co(II)), and nickel (Ni
(II)). A histidine tagged methylene blue (His-MB) is then
introduced to the metal-containing monolayer. Alternating
current voltammetry (ACV) can then be used to characterize
SAM by analysing the AC voltammetric peak consistent with
the formal potential of the MB redox label.
In some embodiments, the probe immobilization strategy
described herein is not permanent and the attached probes can
be effectively displaced by excess free ligands in the solution.
The displacement or “regeneration' step provides a SAM that
can be used multiple times for different sensing applications,
Such as microfluidic-based sensing systems.
The invention will be described in greater detail by way of
specific examples. The following examples are offered for
illustrative purposes, and are not intended to limit the inven
tion in any manner. Those of skill in the art will readily
recognize a variety of noncritical parameters which can be
changed or modified to yield essentially the same results.
EXAMPLES

All reactions were carried out in flame dried glassware
under an atmosphere of dry nitrogen. Solvents were used as
purchased with the exception of THF and CHCl, which
were distilled from Na/PhCO and CaFI, respectively. Thin
layer chromatography (TLC) was performed on 0.25 mm
hard-layer silica G plates; developed plates were visualized
by UV lamp and/or by staining with vanillin, 1% aq. KMnO,
(for unsaturated compounds), I, or phosphomolybdic acid.
NMR spectra were obtained in CDC1s (using residual CHCl

Step 1
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MeO

I

1,2-diiodo-4,5-dimethoxybenzene
To a flame-dried round-bottomed flask equipped with a
short air condenser was added HIO (0.41 equiv. 25.6 mmol.
5.84 g) and methanol (36 mL). The mixture was stirred at rt
and I (0.8 equiv., 50.2 mmol. 12.76 g) was added. The reac
tion was stirred vigorously for 10 min, after which 1,2dimethoxybenzene (1 equiv., 63 mmol, 8.7g, 8.0 mL) was
added in one portion via Syringe. The reaction was then
heated to 70° C. for 5h, producing a slurry comprising white
Solid. The hot solution was poured into dilute aqueous
NaSOs (100 mL) and cooled to rt. The solid was collected
by filtration through a glass frit and washed with two 30 mL
portions of cold methanol and dried in vacuo to afford 1,2diiodo-4,5-dimethoxybenzene (21.07 g. 54 mmol. 86%) as a

white solid. TLC R-0.49 (20% EtOAc/Hex); Melting point
134.5-136.0° C. (134° C. lit.7). H NMR (600 MHz): & 7.25
(s. 2H), 3.85 (s, 6H); 'C NMR (150 MHz): & 149.6, 121.7,
96.1, 56.2.

Step 2
35
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HO

I

HO

I

4,5-diiodobenzene-1,2-diol
To a flame-dried round-bottomed flask was added 1,245

50

&=7.286 ppm) at 300, 400, 500, or 600 MHz for "H NMR
spectra or at 75, 100, 125, or 150 MHz for 'C spectra, as
indicated below. Infrared spectra were recorded as neat ATR
films with selected absorbance reported in wavenumbers

MeO
10

55

(cm).

diiodo-4,5-dimethoxybenzene (1 equiv., 10 mmol. 3.90 g).
The system was evacuated under nitrogen (3x), CHCl (70
mL) was added, and the resulting solution was cooled to 0°C.
BBr (2.5 equiv., 25 mmol. 25 mL of a 1.0 M solution in
CHCl) was then added via syringe pump over 20 min. The
reaction was stirred at 0°C. for 4h then quenched with HO
(50 mL). The separated aqueous layer was then extracted with
EtO (2x75 mL). The combined organic layers were dried
with MgSO filtered through silica, and concentrated in
vacuo to afford 1,2-dihydroxy-4,5-diiodobenzene (3.61 g,

9.99 mmol, quantitative) as an off-white solid. TLCR, 0.50
(50% EtOAc/Hex); Melting point 116.0-116.5°C.; H NMR
(400 MHz, acetone-d): 88.48 (bs, 2H), 7.38 (s. 2H). 'C

NMR (150 MHz, acetone-d): & 146.5, 125.6, 93.7.
Step 3
60

65

TfG)

I

TfG)

I

US 9,079,835 B2
24
gen (3x), followed by the sequential addition of THF (4 mL),
EtN (3 equiv., 6 mmol. 0.85 mL), and ((pent-4-yn-1-yloxy)
methyl)benzene (2.3 equiv., 4.6 mmol. 802 mg) in THF (1
mL). The reaction was stirred for 3 hat rt, filtered through a
pad of silica and concentrated in vacuo. Purification by flash
chromatography (step gradient from Hex to 10% EtOAc/
Hex) afforded 4,5-bis(5-(benzyloxy)pent-1-yn-1-yl)-1,2phenylene bis(trifluoromethanesulfonate) (1.14 g, 1.59

23
4,5-diiodo-1,2-phenylene bis(trifluoromethanesulfonate)
To a flame-dried round-bottomed flask was added 1,2-

dihydroxy-4,5-diiodobenzene (1 equiv. 7.85 mmol. 2.84g),
CHCl (55 mL), and pyridine (5 equiv. 39 mmol. 3.10 g,
3.16 mL). The solution was cooled to 0°C. and Tf.O (2.2
equiv., 17.3 mmol. 4.88 g, 2.91 mL) was added dropwise via
syringe over 10 min. The reaction was stirred for 6 h while
warming to ambient temperature, then cooled to 0°C. and
quenched with HO (30 mL). The separated aqueous layer
was extracted with CHCl (2x30 mL). The combined
organic layers were dried with MgSO and filtered through a
tall pad of silica. The pad was washed carefully with CHC1.
to avoid the elution of impurities, and the filtrate was concen
trated in vacuo to afford 4,5-diiodo-1,2-phenylene bis(trifluo
romethanesulfonate) (4.90 g, 7.82 mmol, quantitative) as an
off-white solid. The product is optionally purified by column

10

mmol, 79%). TLCR-0.27(10% EtOAc/Hex): 'HNMR (600

MHz): 8 7.42 (s. 2H), 7.27-7.39 (10H), 4.56 (s, 4H), 3.65 (t,
4H, J=6.0 Hz), 2.62 (t, 4H, J=7.1 Hz), 1.92-1.98 (m, 4H);

'CNMR (150 MHz): & 138.8, 138.3, 128.4, 128.2, 127.59,

15

127.56, 126.3, 121.7, 119.6, 117.5, 115.3, 98.1, 77.4, 73.0,
68.5, 28.6, 16.5; FTIR: 2859, 2230, 1489, 1433, 1210, 1178,

1135, 1080, 732 cm; HRMS-ESI: calc. for
CHF.O.S.Na (M+Na)": 741.1027. found: 741.1039.

chromatography (10% EtOAc/Hex). TLC R-0.60 (10%
EtOAc/Hex); Melting point 46.5-47.7° C.; H NMR (400
MHz): 87.91 (s. 2H); 'C NMR (100 MHz): 8 139.6, 133.4,
118.5 (q, J-321.0 Hz), 108.0, FTIR: 1429, 1335, 1215,
1125, 1105,868, 788, 745, 689 cm'. HRMS-ESI: calc. for

Step 6

CHFI NaOS (M+Na)": 648.7184. found: 648.7164.

pent-4-yn-1-ylbenzoate
To a flame-dried round-bottomed flask was added pentynol
(1 equiv. 24 mmol. 2.0 g) and CHCl (80 mL). The solution
was cooled to 0°C. and BZC1 (1.2 equiv. 28 mmol. 3.3 mL)
was added dropwise, followed by DMAP (0.1 equiv. 2.4
mmol. 300 mg), and EtN (7 mL). The reaction was warmed
to ambient temperature over 12 h, quenched with 2N HCl (10
mL), extracted with EtOAc (2x40 mL), washed with brine (40
mL) and dried over NaSO. The purified product was iso
lated by concentrating in vacuo and purifying by flash chro
matography (2.5% EtOAc/Hex) to afford pent-4-yn-1-ylben

Step 4

25

((pent-4-yn-1-yloxy)methyl)benzene
To a flame-dried round-bottomed flask was added NaH (2
equiv., 47.6 mmol. 1.9 g of a 60% dispersion in mineral oil).
The solid was washed with hexanes (15 mL), THF (95 mL)
was added and the suspension was cooled to 0°C. Pentynol (1
equiv. 23.8 mmol. 2.0 g) was added drop wise in THF (5 mL),
followed by drop wise addition of BnBr (0.92 equiv., 21.9
mmol. 2.60 mL). The reaction was warmed to ambient tem
perature over 16 h, quenched with saturated aqueous NHCl
(25 mL), and diluted with water (20 mL). The organic layer
was extracted with EtOAc (2x40 mL), washed with brine (40
mL) and dried with NaSO. Product isolation was achieved
by concentration in vacuo and purification by flash column
chromatography to afford (pent-4-yn-1-yloxy)methyl)ben

zene (3.60 g, 20.7 mmol, 94%). TLC R-0.41 (5% EtOAc/
Hex): 'HNMR (300 MHz): 8 7.29-7.44 (5H), 4.55 (s. 2H),
3.61 (t, 2H, J=6.2 Hz), 2.36 (td, 2H, J=7.1, 2.6 Hz), 1.97 (t,
1H, J=2.6 Hz), 1.81-193 (m, 2H). CNMR (75 MHz): 8

30

35

zoate (4.02g, 21.4 mmol. 89%). TLCR-0.57 (10% EtOAc/
Hex): 'HNMR (600 MHz): 88.03-8.07 (2H), 7.53-7.60 (1H),
742-748 (2H), 4.44 (t, 2H, J=6.1 Hz), 2.40 (td, 2H, J–7.3, 2.7
Hz), 1.98-2.05 (overlapping signals, 3H); 'CNMR (150
MHz): 8166.5, 132.9, 130.3, 129.6, 128.3, 83.0, 69.1, 63.4,
27.7, 15.4.

40

45

138.5, 128.4, 127.63, 127.58, 84.0, 73.0, 68.7, 68.5, 28.7,
15.3.

Step 5
50

(CH2)3OBn

TfG)

2^
55

TfG)

Šs
(CH2)5OBn
60

4,5-bis(5-(benzyloxy)pent-1-yn-1-yl)-1,2-phenylene bis(tri
fluoromethanesulfonate)
A flame-dried 20 mL vial fitted with a screw-cap septa was
charged with Pd(PPh3)C1 (0.06 equiv., 0.12 mmol. 84 mg),
Cut (0.12 equiv., 0.24 mmol, 45.6 mg), and 4,5-diiodo-1,2phenylene bis(trifluoromethanesulfonate) (1 equiv., 2 mmol.
1.25 g). The vessel was evacuated and backfilled with nitro

65

(4,5-bis(5-(benzyloxy)pent-1-yn-1-yl)-1,2-phenylene)bis
(pent-4-yne-5,1-diyl)dibenzoate
A flame-dried 20 mL vial fitted with a screw-cap septa was
charged with Pd(PPh)C1 (0.12 equiv., 0.18 mmol. 127mg),
Cut (0.30 equiv., 0.45 mmol. 89.4 mg), and BuNI (3 equiv.,
4.5 mmol. 1.65 g). The vessel was evacuated and backfilled
with nitrogen 3x, followed by the addition of 4.5-Bis(5-ben
Zyloxypent-1-yn-1-yl)-1,2-phenylene bistrifluoromethane
sulfonate in a 5:1 mixture of DMF/EtN (7 mL). The mixture
was stirred for 5 min at rt, and 5-benzoyloxypentyne (4.1
equiv., 6.1 mmol, 980 mg) was added in 1.5 ml of 5:1 DMF/
EtN. The reaction was placed in a 70° C. oil bath for 5.5 h,
cooled to rt, and diluted with 1:1 CHC1/hexanes (40 mL).
The solution was washed with HO (2x20 mL), 1N HCl (40
mL), and brine (40 mL) and dried with MgSO. The product
was isolated by concentrating the crude product in vacuo, and

US 9,079,835 B2
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purifying by flash chromatography (15% EtOAc/Hex) to
afford

(4,5-bis(5-(benzyloxy)pent-1-yn-1-yl)-1,2-phe

nylene)bis(pent-4-yne-5,1-diyl) dibenzoate (930 mg, 1.17

mmol, 79%). TLCR-0.39 (20% EtOAc/Hex): 'HNMR (600

MHz): 8 8.04-8.10 (4H), 7.54-7.60 (2H), 742-747 (4H),
7.39-7.41 (2H), 7.33-7.38 (8H), 727-7.31 (2H), 4.55 (s, 4H),
4.53 (t, 4H, J=6.3 Hz), 3.66 (t, 4H, J=6.2 Hz), 2.70 (t, 4H,
J–7.0 Hz), 2.60 (t, 4H, J–7.0 Hz), 2.11 (quint, 4H, 6.6 Hz),

1.94 (quint, 4H, J=6.6 Hz). CNMR (150 MHz): & 166.5,

138.5, 135.3, 133.0, 130.2, 129.6, 128.38, 128.36, 127.60,
127.56, 125.3, 124.9, 95.0, 93.9, 79.6, 79.1, 73.0, 68.7, 63.7,
28.9, 28.0, 16.7, 16.6; FTIR: 3675, 2988, 2972, 2901, 2229,

10

1716, 1451, 1394, 1269, 1107, 1068, 1027, 900 cm;
HRMS-ESI: calc. for CHO Na (M+Na)": 817.3505.
found: 817.3503.

15

26
of MsCl (3 equiv., 1.02 mmol, 0.08 mL). The reaction was
warmed to ambient temperature over 14 hat which time the
reaction was then quenched with sat. aq. NaHCO (10 mL).
The organic and aqueous layers were separated and the aque
ous layer was extracted with CHCl (3x10 mL). The com
bined organic layers were washed with water (20 mL), dried
with NaSO concentrated in vacuo, and purified by flash
chromatography (45% EtOAc/Hex) to afford (4,5-bis(5((methylsulfonyl)oxy)pentyl)-1,2-phenylene)bis(pentane-5,

1-diyl)dibenzoate (294 mg. 0.37 mmol, 91%). TLC R-0.27
(40% EtOAc/Hex): 'HNMR (600 MHz): 8 8.01-8.11 (4H),
7.54-7.62 (2H), 7.46 (t, 4H, J–7.6), 6.92 (s. 2H), 4.35 (t, 4H,
J=6.6 Hz), 4.26 (t, 4H, J=6.6 Hz), 3.02 (s, 6H), 2.60 (bt, 4H,
J=8.0 Hz), 2.57 (bt, 4H, J=8.0), 1.77-188 (8H), 1.48-1.70

(16H). CNMR (150 MHz): & 166.7, 137.6, 137.3, 132.9,

130.5, 129.9, 129.5, 128.3, 70.1, 65.0, 37.4, 32.2, 32.1, 31.1,
30.8, 29.1, 28.7, 26.2, 25.6; FTIR: 2937, 1714, 1352, 1272,

1173, 1114, 1070,944, 908 cm; HRMS-ESI: calc. for

CHOS-Na (M+Na)": 809.3369. found: 809.3367.
Step 10

(4,5-bis(5-hydroxypentyl)-1,2-phenylene)bis(pentane-5, 1
diyl)dibenzoate
(4,5-bis(5-(benzyloxy)pent-1-yn-1-yl)-1,2-phenylene)bis
(pent-4-yne-5,1-diyl)dibenzoate (1 equiv., 1.11 mmol, 885
mg) was dissolved in 10 mL of 1:1 Methanol/THF. The mix
ture is equally partitioned among 5 straight-walled hydroge
nation vials containing 20 mg of 10% Pd/C EtOAc. The vials
were placed in a hydrogenation chamber and reacted at 40°C.
and 30 psi H for 18 h. The individual reactions were com
bined and filtered through a plug of Celite, concentrated in
vacuo, and purified via flash chromatography (step gradient,
30% EtOAc/Hex to 100% EtOAc) to afford 4,5-bis(5-hy
droxypentyl)-1,2-phenylene)bis(pentane-5,1-diyl)diben

25

30

added
35

zoate (253 mg,0.44 mmol, 40%). TLCR, 0.30 (60% EtOAc/
Hex) (-30% of the saturated dibenzoate derivative and ~10%

of the saturated, monobenzoate derivative were also isolated.

40

These compounds could be resubjected to the reaction con

ditions to provide additional product): 'HNMR (600MHz): 8

8.04-8.10 (4H), 7.54-7.61 (2H), 742-7.50 (4H), 6.94 (s. 2H),
4.36 (t, 4H, J=6.7 Hz), 3.67 (t, 4H, J=6.6 Hz), 2.53-2.68 (8H),

1.80-191 (6H), 1.53-1.72 (16H), 1.44-1.51 (4H); 'CNMR

45

(150 MHz): 8166.7, 137.6, 137.3, 132.8, 130.4, 129.9, 129.5,

1057, 1028 cm; HRMS-ESI: calc. for C.H.O.Na

50

55

(4,5-bis(5-((methylsulfonyl)oxy)pentyl)-1,2-phenylene)bis
(pentane-5,1-diyl)dibenzoate
To a flamed-dried 20 mL vial fitted with a screw-cap septa
was added (4,5-bis(5-hydroxypentyl)-1,2-phenylene)bis
(pentane-5,1-diyl)dibenzoate (1 equiv., 0.34 mmol. 215 mg),
CHCl (4 mL), and EtN (4 equiv., 1.36 mmol, 0.19 mL).
The mixture was cooled to 0°C. and DMAP (0.1 equiv., 0.034
mmol. 4.2 mg) was added followed by the dropwise addition

4,5-bis(5-((methylsulfonyl)oxy)pentyl)-1,2-phe

nylene)bis(pentane-5,1-diyl)dibenzoate (1 equiv., 0.282
mmol. 222 mg) and DMF (2.5 mL). The mixture was cooled
to 0°C. and potassium thioacetate (3 equiv., 0.85 mmol, 97
mg) was added. The reaction was warmed to ambient tem
perature over 14 hat which time the reaction was diluted with
Et2O (20 mL) and water (10 mL). The organic and aqueous
layers were separated and the organic layer was washed with
sat. aq. NaHCOs (3x10 mL), dried with NaSO. The crude
product was then concentrated in vacuo, and purified by flash
chromatography (10% EtOAc/Hex) to afford (4,5-bis(5(acetylthio)pentyl)-1,2-phenylene)bis(pentane-5,1-diyl)

dibenzoate (170 mg, 0.228 mmol, 81%); TLCR, 0.32 (15%
EtOAc/Hex): 'HNMR (600 MHz): 8 8.07 (d, 4H, J–7.3 Hz),

7.58 (t, 2H, J–74 Hz), 7.46 (t, 4H, J=7.8 Hz), 6.92 (s. 2H),
4.36 (t, 4H, J=6.7 Hz), 2.90 (t, 4H, J=7.3 Hz), 2.60 (bt, 4H,
J=7.9 Hz), 2.55 (bt, 4H, J=7.9 Hz), 2.35 (s, 6H), 1.80-1.89

128.3, 65.0., 62.7, 32.5, 32.21, 32.15, 31.2, 30.9, 28.6, 26.1,
25.8: FTIR: 3776,2988,2972,2901, 1717, 1334, 1271, 1067,

(M+Na)": 653.3818. found: 653.3823.

(4,5-bis(5-(acetylthio)pentyl)-1,2-phenylene)bis(pentane-5,
1-diyl)dibenzoate
To a flame-dried 8 mL vial fitted with screw-top cap was

(8H), 1.54-1.70 (8H), 1.44-1.51 (4H); 'CNMR (150 MHz):

& 195.9, 166.7, 137.5, 137.3, 132.8, 130.5, 129.9, 129.5,
128.3, 65.0, 32.3, 32.2, 31.1, 30.9, 30.7, 29.5, 29.1, 28.7,
26.3; FTIR: 3684,3675,2988,2972,2901, 1717, 1688, 1406,

1394, 1383, 1230, 1057, 1028 cm; HRMS-ESI: calc. for
CHsO.S.Na (M+Na)": 769.3573. found: 769.3568.
Step 11

60

65

5.5'-(4,5-bis(5-mercaptopentyl)-1,2-phenylene)bis(pentan
1-ol)
A flame-dried 8 mL vial fitted with a screw-top cap was
charged with (4,5-bis(5-(acetylthio)pentyl)-1,2-phenylene)
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bis(pentane-5,1-diyl)dibenzoate (1 equiv., 0.193 mmol. 144
mg) and THF (2.5 mL). i-BuAIH (DIBAl-H) (12 equiv. 2.3
mmol. 1.55 mL of a nominally 1.5M solution intoluene) was
added dropwise. The reaction was stirred at rt for 2.5h, cooled
to 0°C., and quenched by the careful addition of 4 mL 2N
HC1. The solution was diluted with water (10 mL), extracted
with EtO (3x10 mL), washed with brine (10 mL), and dried
over NaSO. The crude product was then concentrated in
vacuo and purified via flash chromatography (50% EtOAc/
Hex) to afford 5.5'-(4,5-bis(5-mercaptopentyl)-1,2-phe
nylene)bis(pentan-1-ol) (74 mg., 0.163 mmol. 84%). TLC

28
mmol. 36 mL), and CHCl (140 mL). Grubbs 2 catalyst
(0.031 equiv, 0.48 mmol, 416 mg) was dissolved in CHCl
(15 mL) and added to the reaction mixture in one portion. The
reaction was stirred for 4 h, concentrated in vacuo, and puri
fied by flash column chromatography (3% EtOAc/Hex) to
afford (E)-methyl 1 1-chloroundec-2-enoate (3.14 g. 13.6

mmol, 85%). TLC R-030 (5% EtOAc/Hex): 'HNMR (300

10

J=7.3, 1.4 Hz), 1.72-1.85 (m, 2H), 1.26-1.55 (10H); 'CNMR

R=0.19 (45% EtOAc/Hex): 'HNMR (600 MHz): 86.92 (s,

(75 MHz): & 167.2, 149.6, 120.9, 51.4, 45.1, 32.6, 32.2, 29.2,

2H), 3.68 (t, 4H, 6.6 Hz), 2.53-2.61 (12H), 1.56-1.72 (18H),

1.45-1.53 (8H), 1.37 (t, 2H, J–7.9 Hz); CNMR (150MHz):

& 137.6, 137.4, 129.9, 62.9, 33.9, 32.6, 32.3, 32.2, 31.2, 30.8,
28.5, 25.9, 24.6; FTIR: 3353,2930, 2857, 2358, 2338, 1775,

MHz): 86.99 (dt, 1H, J=15.6, 7.0 Hz), 5.84 (dt, 1H, J=15.7,
1.5 Hz), 3.75 (s, 3H), 3.55 (t, 2H, J=6.8 Hz), 2.22 (qd, 2H,
29.0, 28.7, 27.9, 26.8; FTIR: 2928, 2856, 1722, 1657, 1435,

15

1270,1195, 1174, 1041,979,720 cm; HRMS-ESI: calc. for
CHCINaO, (M+Na)": 255.1128. found: 255.1118.
Step 3

1460, 1143 cm; HRMS-ESI: calc. for C.H.O.S.Na

(M+Na)": 477.2837. found: 477.2821.
Example 2

COMe

3,4-Bis(8-mercaptooctyl)hexane-1,6-diol
Step 1

25

Cl(CH2)
COMe

CICH)1 SCH,
30

10-Chlorodecene

To a flame-dried round-bottomed flask was added PPh.
(1.1 equiv. 27.5 mmol. 7.21 g) and THF (65 mL). N-chloro
succinimide (1.1 equiv. 27.5 mmol. 3.67 g) was dissolved in
THF (50 mL) and added dropwise. The mixture was stirred
for 5 min, and 9-decen-1-ol (1 equiv, 25 mmol. 3.91 g) was
added dropwise in THF (30 mL). After 9 h, the volatile
components of the reaction were evaporated and hexanes
(100 mL) and HO (50 mL) were added. The liquid was
decanted and the resulting Solid was washed with hexanes.
The aqueous layer was collected and extracted with hexanes
(2x50 mL). The combined organic layers were washed
sequentially with bleach (30 mL) and brine (50 mL). The
crude product was filtered through a pad of silica (which was
washed with ~400 mL of hexanes) and concentration in vacuo
to afford 10-chlorodecene (3.48 g. 20 mmol. 80%), which
was deemed pure by NMR and used without further purifica

tion. TLC R-0.87 (5% EtOAc/Hex): 'HNMR (400 MHz): 8
5.84 (ddt, 1H, J=17.4, 10.3, 6.7 Hz), 5.02 (ddd, 1H, J=17.4,
2.0, 3.6 Hz), 4.93-4.98 (m. 1H), 3.56 (t, 2H, J=6.5 Hz),
2.02-2.12 (m, 2H), 1.74-1.84 (2H), 1.27-1.50 (10H):

To a flame-dried round-bottomed flask, evacuated and

35

40

45

50

'CNMR (100 MHz): 8 139.2, 114.2, 45.2, 33.8, 32.7, 29.3,
29.0, 28.88, 28.85, 26.88.

55

Step 2
O

al-N-OMe

60

To a flame-dried round-bottomed flask, evacuated and

backfilled with nitrogen (3x) and equipped with a dropping
funnel was added (E)-methyl 1 1-chloroundec-2-enoate (1
equiv, 11.9 mmol, 2.77 g), THF (25 mL), MeOH (0.9 mL),
and HMPA (25 mL). SmI (2.1 equiv, 25 mmol, 250 mL of a
nominally 0.1 M solution in THF) was added rapidly in one
portion via dropping funnel. The reaction was stirred for 0.5
h, quenched by the dropwise addition of 2 NHCl (20 mL),
and diluted with HO (100 mL) and EtO (100 mL). The
layers were separated, and the aqueous layer was extracted
with EtO (2x50 mL). The combined organic layers were
washed with brine (2x50 mL), dried with MgSO, concen
trated in vacuo, and purified by flash column chromatography
(step-wise gradient 5% to 8% EtOAc/Hex) to afford Dim
ethyl 3,4-bis(8-(chloro)octyl)hexanedioate (1.76 g) as a mix
ture of stereoisomers and an unidentified impurity. TLC

R-0.43 (10% EtOAc/Hex).
The mixture can be used directly in the next reaction.
Alternatively, the impurity can be removed by reacting the
product (47 mg) with NaBH (3.8 mg) in THF (1 mL). After
3.5h, the reaction was quenched with 3 mL HO, extracted
with CHCl (3x5 mL), dried with NaSO concentrated in
vacuo, and purified by flash column chromatography (10%
EtOAc/Hex) to afford purified Dimethyl 3,4-bis(8-(chloro)

octyl)hexanedioate (26 mg). TLC R-0.43 (10% EtOAc/
Hex): 'HNMR (300 MHz): 83.68 (s, 6H), 3.55 (t, 4H, J=6.8
Hz), 1.91-2.35 (6H), 1.71-1.85 (4H), 1.13-1.50 (24H);

'CNMR (75 MHz): & 173.94, 173.88, 51.54, 51.51, 45.14,

(E)-Methyl 11-chloroundec-2-enoate
backfilled with nitrogen (3x), was added 10-chlorodecene (1
equiv, 16 mmol. 2.79 g), methyl acrylate (25 equiv. 395

Dimethyl 3,4-bis(8-(chloro)octyl)hexanedioate
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37.4, 37.2, 36.2, 35.7, 32.6, 31.5, 30.7, 29.6, 29.3, 28.8, 27.4,
27.3, 26.8; FTIR: 2927, 2855, 1735, 1435, 1251, 1191, 1165,

1016, 722 cm; HRMS-ESI: calc. for C.H.ClNaO.
(M+Na)": 489.2514. found: 489,2506.

US 9,079,835 B2
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Step 4

found: 429.2825; meso: 'HNMR (400 MHz): a 3.59-3.76
(4H), 2.54 (q, 4H, J=7.3 Hz), 1.87 (bs, 2H), 1.08-1.68 (36H):
CNMR (100 MHz): 8 61.9, 36.7, 34.0, 33.8, 30.7, 30.0,

COMe

29.5, 29.1, 28.4, 28.0, 24.7: FTIR: 3329, 2922, 2852, 1463,

H

1051, 721 cm; HRMS-ESI: calc. for CHNaOS,

AcS(CH2)3

(M+Na)": 429.2837. found: 429.2829.
Example 3

AcS (CH2)s
H

COMe

Dimethyl 3,4-bis(8-(acetylthio)octyl)hexanedioate
To a flame-dried 20 mL vial fitted with a screw-top septa
cap was charged with pure dimethyl 3,4-bis(8-(chloro)octyl)
hexanedioate (1 equiv, 0.46 mmol. 215 mg, mixture of Stere
oisomers) and DMF (4 mL). KSAc (5 equiv, 2.3 mmol. 263
mg) was added in one portion and the reaction was stirred for
14 h at rt, diluted with EtO (25 mL), washed with sat. aq.
NaHCO (2x10 mL), dried with NaSO, concentrated in
vacuo, and purified by flash column chromatography (step
wise gradient 5% to 10% EtOAc/Hex) to afford Dimethyl
3,4-bis(8-(acetylthio)octyl)hexanedioate (215 mg. 85%).

TLCR-0.32 (10% EtOAc/Hex): 'HNMR (300 MHz): 83.68
(s, 6H), 2.87 (t, 4H, J–7.3 Hz), 1.92-1.40 (12H), 1.51-1.64

Step 1
15

25

(4H), 1.16-141 (24H); 'CNMR (75 MHz): & 1960, 174.0,

173.9, 51.5,374,37.2,36.2,35.7, 31.5, 30.7, 30.6, 29.7, 29.5,
29.4, 29.13, 29.06, 28.8, 27.4, 27.3; FTIR: 2926, 2854, 1736,

1689, 1435, 1353, 1250, 1165, 1133, 1106, 1013,953 cm;

HRMS-ESI: calc. for CH-NaOS (M+Na)": 569.2947.

30

found: 569.2945.

Stereochemical assignment was made by chiral HPLC
analysis of the product mixture (ChiralPak IC, 90:10 Hex:
iPrOH, 0.5 mL/min: UV detection was performed at 254 nm).
The racemic (rac) Stereoisomer eluted as two peaks at 114 and

(Z)-3,4-bis(8-mercaptooctyl)hex-3-ene-1,6-diol

10

THPO(CH2)s

E

H

9-Decyn-1-ol tetrahydropyranyl ether
To a flame-dried round-bottomed flask was added 9-decyn
1-ol (1 equiv. 32.4 mmol. 5.00 g), dihydropyran (1.5 equiv,
48.6 mmol. 4.09 g, 4.5 mL), CHCl (50 mL), and PPTS (0.1
equiv, 3.24 mmol. 800 mg). The reaction was stirred for 16h
at rt and quenched with sat. aq. NaHCOs (40 mL). The layers
were separated and the aqueous layer was extracted with
CHCl (2x20 mL). The combined organic layers were
washed with HO (30 mL), dried with NaSO, concentrated
in vacuo, and purified by flash column chromatography (5%
EtOAc/Hex) to afford 9-Decyn-1-ol tetrahydropyranyl ether

(7.55g, 31.7 mmol, 98%). TLC R-030 (5% EtOAc/Hex):
'HNMR (600 MHz): 8 4.55-4.62(1H), 3.83-3.91 (m, 1H),

3.70-3.78 (m. 1H), 3.48-3.55 (m, 1H), 3.36-3.43 (m, 1H),
2.19 (td, 2H, J, -7.1 Hz, J-2.6 Hz), 1.95 (t, 1H, J–2.6),
1.80-1.89 (1H), 1.69-1.76 (1H), 1.50-1.63 (8H), 1.28-144
35

119 min; the mesostereoisomer eluted at 142 min. The ratio

(8H); 'CNMR (150 MHz): & 98.8, 84.7, 68.1, 67.6, 62.3,

30.8, 29.7, 29.3, 29.0, 28.7, 28.5, 26.2, 25.5, 19.7, 18.4.

Step 2

of meso-rac. was 1.44:1.

Step 5
THPO(CH2)s

COMe

40

45

H

3,4-Bis(8-mercaptooctyl)hexane-1,6-diol
To a flame-dried 20 mL vial fitted with a screw-top septa
cap was charged with dimethyl 3,4-bis(8-(acetylthio)octyl)
hexanedioate (1 equiv, 0.34 mmol, 187 mg, mixture of stere
oisomers) and THF (4.5 mL). DIBAl-H (12 equiv. 4.1 mmol.
2.7 mL of a nominally 1.5M solution in toluene) was added
dropwise. The reaction was stirred for 3 hat rt, quenched by
careful addition of 2 NHCl (5 mL), diluted with 10 mL sat.
aq. NHCl (10 mL), and extracted with EtO(3x15 mL). The
combined organic layers were washed with brine (1x15 mL),
dried with NaSO, concentrated in vacuo, and purified by
flash column chromatography (35% EtOAc/Hex) to afford
rac-3,4-Bis(8-mercaptooctyl)hexane-1,6-diol (41 mg, 30%)
and meso-3,4-Bis(8-mercaptooctyl)hexane-1,6-diol (49 mg,

stirred for 30 min at -78° C. and then added to a solution of
50

55

28.0, 24.6; FTIR: 3323, 2922, 2852, 1463, 1051, 722 cm;
HRMS-ESI: calc. for CH-NaOS (M+Na)": 429.2837.

methyl chloroformate (1.5 eq, 47.6 mmol. 4.50 g, 3.7 mL) in
THF (20 mL) dropwise via cannula. The reaction was stirred
for 30 minat -78°C., then warmed tort over 1 hand quenched
dropwise with HO (40 mL). The layers were separated and
the aqueous layer was extracted with EtO (2x25 mL). The
combined organic layers were dried with NaSO, evaporated
in vacuo, and purified by flash column chromatography (step
gradient, 5% EtOAc/Hex to 10% EtOAc/Hex) to afford
Methyl-11-(tetrahydro-2H-pyran-2-yl)oxy-undecynoate

(8.50g, 28.7 mmol, 90%). TLC R-0.33 (10% EtOAc/Hex)
HNMR (600 MHz): 8 4.55-4.61 (1H), 3.84-3.91 (m, 1H),

60

49%). TLC rac-R-0.57 (50% EtOAc/Hex), meso-R-0.38
(50% EtOAc/Hex); rac: 'HNMR (400 MHz): & 3.60-3.79
(4H), 2.54 (q, 4H, J=7.3 Hz), 1.14-1.68 (38H); 'CNMR (100
MHz): 8 61.6, 35.8, 34.0, 33.7, 30.7, 30.0, 29.5, 29.1, 28.3,

Methyl-11-(tetrahydro-2H-pyran-2-yl)oxy-undecynoate
A flame-dried round-bottomed flask was charged with
9-decyn-1-ol tetrahydropyranyl ether (1 equiv. 31.7 mmol.
7.55g) and THF (40 mL), and cooled to -78° C. n-Bulli (1.1
equiv. 34.9 mmol. 21.8 mL of a nominally 1.6M solution in
hexanes) were added dropwise over 5 min. The reaction was

3.70-3.78 (m plus ovlp. S. 4H), 3.47-3.54 (m. 1H), 3.39 (dt,
1H, J,-9.6 Hz, J-6.7 Hz), 2.33 (t, 2H, J=7.1 Hz), 1.80-1.89
(1H), 1.68-1.76 (1H), 1.50-1.63 (8H), 1.28-144 (8H):

CNMR (150 MHz): & 1543, 98.9, 89.9, 72.9, 67.6, 62.3,

65

52.5, 30.8, 29.7, 29.2, 28.9, 28.7, 27.5, 26.2, 25.5, 19.7, 18.6;
FTIR: 2932, 2856, 2236, 1714, 1434, 1249, 1075, 1023,752

cm'; HRMS-ESI: calc. for CH-NaO (M+Na)":
3.19.1885. found: 319.1887.

US 9,079,835 B2
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Step 3
SnBus

THPO(CH;1 S
COMe

(E)-methyl 11-((tetrahydro-2H-pyran-2-yl)oxy)-3-(tributyl
Stannyl)undec-2-enoate
To a flame-dried round-bottomed flask equipped with two
dropping funnels was added iPr-NH (2.5 equiv. 71.4 mmol.
7.22 g, 10.0 mL) and THF (225 mL) and the solution was
cooled to 0°C. nBuLi (2.5 equiv. 71.4 mmol. 44.6 mL of a
nominally 1.6 M solution in hexanes) was added dropwise
and the reaction was stirred for 30 min at 0°C. nBuSnH (2.3
equiv, 65.6 mmol. 19.1 g, 17.7 mL) was added dropwise and

10

15

30.8, 29.8, 29.77, 29.68, 29.5, 29.0, 27.4, 26.3, 25.5, 19.7,
13.7, 10.0; FTIR: 2918, 2852, 1717, 1591, 1456, 1431, 1351,

617.4039.

Step 5

THPO(CH2)s

30

Dimethyl 3,4-bis(8-((tetrahydro-2H-pyran-2-yl)oxy)octyl)
35

40

45

61.13111.
50

COMe

2

THPO(CH2)s
COMe

1189, 1162, 1136, 1121, 1077, 1022,867 cm; HRMS-ESI:

THPO(CH2)s

COMe

25

calc. for C.H.NaOSn (M+Na)": 611.3104. found:
Step 4

(20H); 'CNMR (125 MHz): & 166.5, 1618, 117.6, 98.8,
1163, 1136, 1078, 1023,986, 905, 868, 814 cm; HRMS

(29H), 0.93-0.99 (5H), 0.91 (t, 9H, J=7.3 Hz); CNMR (125

MHz): & 174.9, 164.6, 127.0, 98.8, 67.7, 62.3, 50.8, 35.3,

3.83-3.92 (2H), 3.69-3.77 (s plus ovlp.m., 8H), 3.47-3.55 (m,
2H), 3.38 (dt, 2H, J, -9.6 Hz, J-6.7 Hz), 2.72-2.84 (4H),
1.78-1.89 (2H), 1.69-1.76 (2H), 1.50-1.63 (12H), 1.28-141

ESI: calc. for CHssNaOs (M+Na)": 617.4029. found:

25.5 mmol, 90%). TLC R-0.30 (5% EtOAc/Hex): 'HNMR

(500 MHz): 8 5.86-6.03 (m, 1H), 4.56-4.62 (m, 1H), 3.85
3.92 (m, 1H), 3.74 (dt, 1H, J, -9.6 Hz, J-6.9 Hz), 3.70 (s,
3H), 3.47-3.54 (m, 1H), 3.39 (dt, 1H, J=9.6 Hz, J-6.7 Hz),
2.78–2.97 (m,2H). 1.79-190 (1H), 1.69-1.77 (1H), 1.27-1.65

dioate (6.27g, 10.5 mmol, 83%). TLCR, 0.19 (10% EtOAc/
Hex): 'HNMR (500 MHz): 8 5.84 (bs, 2H), 4.55-461 (2H),

67.7, 62.3, 51.2, 30.8, 29.7, 29.6, 29.4, 29.3, 29.1, 28.7, 26.2,
25.5, 19.7: FTIR: 2927, 2855, 1718, 1628, 1433, 1351, 1193,

the reaction was stirred for 30 min at 0°C. The reaction was

cooled to -50° C. by the controlled addition of dry ice to
acetone and CuCN (2.3 equiv, 65.6 mmol. 5.88 g) was added
in one portion. The reaction was stirred for 45 min at -50° C.
then cooled to -78° C. MeOH (1.70 mL) was added followed
by the addition of methyl-11-(tetrahydro-2H-pyran-2-yl)
oxy-undecynoate (1 equiv. 28.5 mmol, 8.46 g) in THF (85
mL) in one portion. The reaction was stirred at -78°C. for 10
min, then quenched with 170 mL of aq. NHCl/NH-OH (pH
~8) and diluted with 150 mL EtO. The reaction was warmed
to rt (orange color is discharged and Solution turns colorless),
the layers were separated, and the aqueous layer extracted
with EtO (3x120 mL). The combined organic layers were
washed with aq. NHC1/NH-OH (pH-8) (100 mL), and brine
(120 mL), dried with NaSO concentrated in vacuo, and
purified by flash column chromatography (step gradient, Hex
to 5% EtOAc/Hex) to afford (E)-methyl 11-((tetrahydro-2H
pyran-2-yl)oxy)-3-(tributylstannyl)undec-2-enoate (15.1 g,

32
stirred for 3 hat rt, quenched with aq. NHCl/NH-OH (pH
~8) (35 mL), and stirred for 2 h open to the air. The solution
was diluted with H2O (50 mL) and EtO (50 mL). The layers
are separated and the aqueous layer was extracted with Et2O
(2x50 mL). The combined organic layers were washed with
brine (75 mL), dried with MgSO, concentrated in vacuo, and
purified by flash chromatography (step gradient, 10% EtOAc/
Hex to 15% EtOAc/Hex) to afford (2E,4E)-dimethyl 3,4-bis
(8-((tetrahydro-2H-pyran-2-yl)oxy)octyl)hexa-2,4-diene

hex-3-enedioate

A flame-dried round-bottomed flask was charged with Mg
(15 equiv. 18.75 mmol. 456 mg) and equipped with a con
denser. (2E,4E)-dimethyl 3,4-bis(8-((tetrahydro-2H-pyran
2-yl)oxy)octyl)hexa-2,4-dienedioate (1 equiv. 744 mg, 1.25
mmol) was added in MeOH (16 mL) and the reaction was
stirred at rt. After ~30 min, the reaction began refluxing and
was left to reflux for ~45 min upon which time the reaction
was permitted to cool to it, quenched with sat. aq. NHCl (5
mL), diluted with EtO (15 mL), and H2O (20 mL). The liquid
was decanted into a separatory funnel and the remaining Solid
was washed several times with EtO. The layers were sepa
rated and the aqueous layer extracted with EtO (3x20 mL).
The combined organic layers were washed with brine (30
mL), dried with NaSO and concentrated in vacuo to afford
Dimethyl 3,4-bis(8-((tetrahydro-2H-pyran-2-yl)oxy)octyl)
hex-3-enedioate (565 mg crude mass, ~90% pure by

HNMR, 0.95 mmol, 76%) as an inseparable 2:1 mixture of
55

isomers which was used in the next reaction without further

purification. TLCR-0.41 (20% EtOAc/Hex): HNMR (500
THPO(CH)

N
COMe

(2E,4E)-dimethyl 3,4-bis(8-((tetrahydro-2H-pyran-2-yl)
oxy)octyl)hexa-2,4-dienedioate
To a flamed-dried round-bottomed flask was added (E)methyl 11-((tetrahydro-2H-pyran-2-yl)oxy)-3-(tributylstan
nyl)undec-2-enoate (1 equiv, 25.5 mmol. 15.0 g), DMF (30
mL), and CuCl (3 equiv. 76.5 mmol.7.57g). The reaction was

60

MHz): & 4.61-4.56 (2H), 3.91-3.85 (2H), 3.77-3.70 (2H),
3.67 (s, 4H), 3.66 (s. 2H), 3.54-3.47 (2H), 3.42-3.35 (2H),
3.12 (s, 2.7H), 3.11 (s, 1.3H), 2.16-2.07 (4H), 1.90-1.80 (2H),

1.76-1.69 (2H), 1.63-1.49 (12H), 1.40-1.24 (20H); 'CNMR
(125 MHz): 8 172.4, 172.2, 130.7, 130.6, 98.9, 67.7, 62.4,

65

51.8, 37.6, 37.2, 33.3, 32.9, 30.8, 29.8, 29.71, 29.68, 29.49,
29.47, 28.3, 28.1, 26.2, 25.5, 19.7; FTIR: 2926, 2854, 1737,
1434, 1295, 1200, 1156, 1136, 1119, 1078, 1022,988, 869,

814 cm; HRMS-ESI: calc. for CHNaOs(M+Na)":
619.418.6. found: 619.4174.

US 9,079,835 B2
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Step 6

'CNMR (125 MHz): & 172.3, 1722, 130.7, 130.6, 70.20,
70.18, 51.8, 37.6, 37.4, 37.2, 33.2, 32.8, 31.6, 29.58, 29.55,
29.33, 29.29, 29.1, 29.00, 28.97, 28.3, 28.0, 25.4; FTIR:
2929, 2855, 1732, 1435, 1350, 1170,972, 935, 833, 721

COMe

cm; HRMS-ESI: calc. for CHsNaOS (M+Na)":

HO(CH2)3

6O7.2587. found: 6O7.2570.

Step 8
HO(CH2)s
COMe

Dimethyl 3,4-bis(8-hydroxyoctyl)hex-3-enedioate
A flamed-dried 20 mL vial fitted with screw-cap septa was
charged with Dimethyl 3,4-bis(8-((tetrahydro-2H-pyran-2yl)oxy)octyl)hex-3-enedioate (1 equiv, 0.855 mmol. 510
mg), MeOH (10 mL) and PTSA (0.1 equiv, 0.086 mmol. 16.4
mg). The reaction was stirred at rt for 14h, quenched with sat.
aq. NaHCO, and diluted with CHCl (20 mL) and HO (10
mL). The layers were separated and the aqueous layer was
extracted with CHCl (2x20 mL). The combined organic
layers were washed with HO (20 mL), dried with NaSO,
concentrated in vacuo, and purified by flash chromatography
(65% EtOAc/Hex) to afford Dimethyl 3,4-bis(8-hydroxyoc
tyl)hex-3-enedioate (321 mg, 0.75 mmol, 88%) as an insepa

10

AcS (CH)8

15

'CNMR (125 MHz): & 1744, 1743, 130.7, 130.6, 62.99,

25

30

51.8, 37.6, 37.2, 33.2, 32.82, 32.75, 29.6, 29.5, 29.44, 29.35,
29.32, 28.3, 28.0, 25.71, 25.68: FTIR: 3375, 2926, 2854,

1736, 1434, 1332,1242, 1192,1155, 1048 cm; HRMS-ESI:

calc. for CH-NaO (M+Na)": 451.3036. found: 451.3022.
Step 7

35

Dimethyl 3,4-bis(8-(acetylthio)octyl)hex-3-enedioate
To a flamed-dried 20 mL vial fitted with a screw-cap septa
was added Dimethyl 3,4-bis(8-((methylsulfonyl)oxy)octyl)
hex-3-enedioate (1 equiv, 0.46 mmol. 269 mg) and DMF (4
mL). The solution was cooled to 0°C. and KSAc (4 equiv,
1.84 mmol. 210 mg) was added. The reaction was allowed to
come to ambient temperature over 15h then diluted with EtO
(25 mL) and H2O (10 mL). The layers were separated and the
organic layer was washed with sat. aq. NaHCO, (3x10 mL),
dried with NaSO, concentrated in vacuo, and purified by
flash column chromatography (15% EtOAc/Hex) to afford
Dimethyl 3,4-bis(8-(acetylthio)octyl)hex-3-enedioate (223
mg, 0.405 mmol. 89%) as an inseparable 2:1 mixture of
isomers (Note: partial separation could beachieved, however,

both isomers were carried on to the next step). TLC R-0.43
and 0.38 (20% EtOAc/Hex): 'HNMR (500 MHz): 83.68 (s,

4H), 3.66 (s.2H), 3.12 (s.2.7H), 3.11 (1.3H), 2.84-2.90 (ovlp.
t’s, 4H), 2.34 (s, 6H), 2.07-2.16 (4H), 1.52-1.61 (4H), 1.19

1.40 (20H); CNMR (125 MHz): & 196.1, 1274, 172.2,

COMe
MsO(CH)8

AcS (CH2)s

COMe

rable 2:1 mixture of isomers. TLC R-0.19 (50% EtOAc/
Hex): 'HNMR (500 MHz): 83.61-3.70 (t plus two ovlp. s.
10H, J=6.7 Hz), 3.13 (s, 2.7H), 3.11 (s, 1.3H), 2.07-2.18 (4H),
1.57 (quint., 4H, J=7.8 Hz), 1.49 (bs, 2H), 1.26-1.40 (20H):

COMe

40

130.7, 130.6, 51.8, 37.6, 37.2, 33.3, 32.8, 30.7, 29.7, 29.6,
29.5, 29.38, 29.36, 29.13, 29.09, 29.07, 28.80, 28.78, 28.3,
28.0, FTIR: 2924, 2850, 1733, 1691, 1431, 1338, 1190,1153,

1134, 995, 951, 722 cm; HRMS-ESI: calc. for

CHNaOS (M+Na)":567.2790, found: 567.2770.
Step 9
COMe

45

Dimethyl 3,4-bis(8-((methylsulfonyl)oxy)octyl)hex-3-ene
dioate

To a flamed-dried 20 mL vial fitted with a screw-cap septa
was added Dimethyl 3,4-bis(8-hydroxyoctyl)hex-3-enedio
ate (1 equiv, 0.642 mmol. 275 mg), CHCl (6 mL), and EtN
(4 equiv, 2.57 mmol, 0.36 mL). The mixture was cooled to 0°
C. and DMAP (0.1 equiv, 0.064 mmol, -8 mg) was added
followed by the dropwise addition of MsCl (3 equiv, 1.93
mmol, 0.15 mL). The reaction was allowed to come to ambi
ent temperature over 14 h at which time the reaction was
quenched with sat. aq. NaHCO (10 mL). The layers were
separated and the aqueous layer was extracted with CH2Cl2
(3x15 mL). The combined organic layers were washed with
H2O (20 mL), dried with NaSO, concentrated in vacuo, and
purified by flash column chromatography (45% EtOAc/Hex)
to afford Dimethyl 3,4-bis(8-((methylsulfonyl)oxy)octyl)
hex-3-enedioate (309 mg, 0.526 mmol. 82%) as an insepa

rable 2:1 mixture of isomers. TLC R-0.24 (45% EtOAc/
Hex): 'HNMR (500 MHz): 8 420-4.25 (ovlp. ts, 4H), 3.68
(s, 4H), 3.66 (s. 2H), 2.13 (s, 2.7H), 3.11 (s, 1.3H), 3.02 (s,
6H), 2.07-2.17 (4H), 1.71-1.79 (4H), 1.25-145 (20H):

50
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(Z)-3,4-bis(8-mercaptooctyl)hex-3-ene-1,6-diol
To a flamed-dried 20 mL vial fitted with a screw-cap septa
was added Dimethyl 3,4-bis(8-(acetylthio)octyl)hex-3-ene
dioate (1 equiv, 0.36 mmol, 196 mg) and THF (4.5 mL).
DIBAl-H (12 equiv. 4.3 mmol. 2.9 mL of a nominally 1.5 M
solution in toluene) was added dropwise at rt. The reaction
was stirred at rt for 2 hand quenched by the careful addition
of 2N HCl (3 mL). The solution was transferred to a sepratory
funnel and diluted with sat. aq. NHCl (15 mL) and EtO (15
mL). The layers were separated and the aqueous layer
extracted with EtO (2x15 mL). The combined organic layers
were washed with brine (20 mL), dried with NaSO con
centrated in vacuo, and purified by flash column chromatog
raphy (40% EtOAc/Hex) to afford (Z)-3,4-bis(8-mercaptooc
tyl)hex-3-ene-1,6-diol (82.8 mg, 0.205 mmol. 57%). TLC

R-0.41 (50% EtOAc/Hex); Mp=67.4-68.2° C.; HNMR

US 9,079,835 B2
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(600 MHz): 83.64 (t, 4H, J–6.9 Hz), 2.54 (q, 4H, J–7.4 Hz),
2.35 (t, 4H, J=7.0 Hz), 2.08-2.02 (4H), 1.68 (bs, 2H), 1.62

(quint, 4H, J=7.4 Hz), 1.42-1.27 (22H); CNMR (150

36
dazole is immobilized on a gold electrode surface via a thiol
gold bond. In the presence of a divalent cation, Such as NiCII),
the imidazole chelating agent can efficiently capture His

MHz): & 132.4, 61.3, 34.6, 34.0, 31.7, 29.7, 29.5, 29.2, 29.0,

MB.

28.3, 24.6; FTIR:3402, 3349, 2923, 2850, 1465, 1348, 1028,

721 cm; HRMS-ESI: calc. for CH-NaOS (M+Na)":

427.2680. found: 427.2679.

Example 4
10

His-Tagged Methylene Blue Peptide Immobilized on
Imidazole-Ni-Modified SAM
Materials

1-(11-mercaptoundecyl)imidazole, 8-mercapto-1-octanol,
sulfuric acid (95%), sodium chloride, monosodium phos
phate, disodium phosphate, nickel (II) chloride, imidazole,
and ethylenediaminetetraacetic acid (EDTA) were purchased
from Sigma-Aldrich (St. Louis, Mo.) and used as received
without further purification. Diamond suspension (0.1 um)
was purchased from Buehler (Lake Bluff, Ill.). Methylene
blue histidine-tagged peptide: (His-MB) (His-His-His-His
His-His-Lys-Methylene blue) was purchased from Xaia Cus
tom Peptides (Göteborg, Sweden).
All solutions were prepared with deionized water and puri
fied through a Millipore Synergy system (18.2 MS2 cm, Mil
lipore, Bedford, Mass.). The phosphate buffer saline (PBS)
used in this study contained 8.02 mM NaHPO, 1.98 mM
NaH2PO, and 100 mM NaCl (pH 7.4).
Instrumentation

15

The electrodes were then rinsed with deionized water and

Hist-MB (10-15 uL of a 5 uM solution in PBS) was drop
25

30

Electrochemical measurements were performed at room
temperature (22+1°C.) using a CHI 1040A Electrochemical
Workstation (CH instruments, Austin, Tex.). Polycrystalline

golddisk electrodes with a geometric area of 0.0314 cm were

purchased from CH instruments (Austin, Tex.). The counter
electrode (platinum wire electrode) and the reference elec
trode (Ag/AgCl, 3M KCl) were also purchased from CH

35

Instruments.
Procedure

Gold electrodes were primed by polishing with a 0.1 um
diamond Suspension, rinsing with deionized water and Soni
cating in a low power Sonicator for about five minutes to
remove bound particulates. The electrodes were electro
chemically cleaned by a series of oxidation and reduction
cycles in 0.5 MHSO. The area of each electrode was deter
mined by measuring the charge associated with a gold oxide
stripping peak formed after the cleaning process in 0.05 M
HSO4. After cleaning, the gold disk electrodes were rinsed
with deionized water, dried with nitrogen and placed directly
in a 100 uM solution of 1-(11-mercaptoundecyl)imidazole in

40
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ethanol and deionized water and placed in a 2 mM solution of
8-mercapto-1-octanol for 3 hours. The electrodes were then
rinsed with ethanol and deionized water.
55

for 30 minutes. The electrodes were then rinsed with deion

ized water and histidine-tagged methylene blue (His-MB)
(10-150 uL of 5uM solution in PBS) was dropcasted onto the

casted onto the electrodes for 1 hour. The electrodes were then

rinsed thoroughly by washing with deionized water (1x5
mL), ethanol (1x2 mL), deionized water (1x5 mL), 1 MNaCl
(1 M, 1x2 mL), and deionized water (1x5 mL). The electrodes
were subsequently placed in a fresh aliquot of PBS. AC vol
tammograms were collected after the monolayer had equili
brated to achieve a stable methylene blue peak current.
FIG. 2A shows ACV data for His-MB immobilized on an
imidazole-Ni SAM before and after displacement by free
imidazole. FIG. 2B illustrates the displacement-replacement
profile obtained during the experiment. As shown in FIG. 2B,
the monolayer of the invention is very stable and can Sustain
two distinct displacement and replacement cycles without
Substantial changes in the capacitance current.
Example 5
Electrochemical Biosensor for Detecting Anti-Peanut
Antibody (IgY)

ethanol for 10 minutes. Next, the electrodes were rinsed with

After formation of the self-assembled monolayer (SAM),
electrodes containing the SAM were placed in a solution of
NiCl, (100 mM) in PBS supplemented with EDTA (1 mM)

The His-MB-bound electrodes were placed in an electro
chemical cell containing PBS and analysed by alternating
current voltammetry (ACV). AC voltammograms were
recorded from -0.05 V to -0.45 V vs. Ag/AgCl at 10 Hz and
with an AC amplitude of 25 mV. The electrodes were equili
brated in PBS until a stable methylene blue peak current was
obtained. In the displacement step, captured His-MB was
displaced from the SAM by adding a high concentration of
free imidazole (250 mM in PBS) to the electrochemical cell.
The methylene blue peak current was then monitored for
20-25 minutes. After displacement, the electrochemical cell
was rinsed with deionized water and placed in a fresh aliquot
of PBS for electrode re-equilibration. AC voltammograms
were collected after the monolayer had equilibrated to
achieve a stable methylene blue peak current.
In the replacement step, His-MB was reintroduced to the
SAM construct by incubating the electrodes in a new aliquot
ofNiCl, (100 mM in PBS) and EDTA (1 mM) for 30 minutes.

60

In this example, the imidazole-SAM prepared in Example
4 was used in an electrochemical peptide-based sensor for
direct detection of an anti-peanut allergen antibody (Igy)
using a His-tagged peptide epitope from Arah2, a major pea
nut allergen (His-Arah2-10-MB) (His-His-His-His-His
His-Ser-Glu-Asp-Pro-Tyr-Ser-Pro-Ser-Pro-Tyr-Lys-Methyl
ene blue, purchased from Xaia Custom Peptides, Göteborg,
Sweden). The antibody target, IgY-APP-3, was purchased
from Gallus Immunotech Inc. (Ontario, Canada). IgY-APP-3
antibodies were obtained from hen eggs immunized with
Arachis hypogaea protein extract.
Gold electrodes containing the imidazole-SAM were
placed in a solution of NiCl, (100 mM) in PBS supplemented
with EDTA (1 mM) for 30 minutes. The electrodes were then
rinsed with deionized water and histidine-tagged Arah2-10
MB (10-15 uL of 5uM solution in PBS) was dropcasted onto

electrodes for 1 hour. The electrodes were then rinsed thor

the electrodes for 1 hour. The electrodes were then rinsed

oughly by washing with deionized water (1x5 mL), ethanol
(1x2 mL), deionized water (1x5 mL), 1 M NaCl (1 M. 1x2
mL), and deionized water (1x5 mL)
FIG. 1 is a schematic, depicting the immobilization of
His MB onto the imidazole-Ni SAM prepared in this
example. As shown in FIG. 1, 1-(11-mercaptoundecyl)imi

thoroughly by washing with deionized water (1x5 mL), etha
nol (1x2 mL), deionized water (1x5 mL), 1 MNaCl (1 M, 1x2
mL), and deionized water (1x5 mL)
The His-Arah2-10-MB-bound electrodes were placed in
an electrochemical cell containing PBS and analysed by alter
nating current Voltammetry (ACV). AC Voltammograms
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were recorded from -0.05 V to -0.45 V vs. Ag/AgCl at 10 Hz
and with an AC amplitude of 25 mV. The electrodes were
equilibrated in PBS until a stable methylene blue peak current
was obtained. Antibodies against Arachis hypogaea protein
extract (IgY-APP-3) were added consecutively in the follow
ing concentrations: 0.5, 1, 10, 20, 30, 40, and 50 nM.
FIG. 3 shows ACV data for His-Arah2-10-MB immobi
lized on the imidazole-Ni SAM in the absence and presence
of various concentrations of the anti-peanut IgY. As shown in
FIG. 3, a large MB reduction peak is present, indicating
Successful immobilization of the His-tagged peptide probe.
The sensor responds to the target antibody in a concentration
dependent manner, exhibiting an experimental detection limit
of 500 mM. Control experiments further suggest that the
binding is specific since negligible cross reactivity is
observed when the sensor was interrogated with random IgY
(data not shown).
Example 6

5

Displacement of his-Tagged Methylene Blue from
Sam Construct Using Histamine and Histidine
10

15

His-Tagged Methylene Blue Immobilized on
Imidazole-Co and Imidazole-Zin Modified Sam

In this example, 1 imidazole-Co and imidazole-Zn SAM
constructs were prepared and analysed by ACV. Specifically,
1-(11-mercaptoundecyl)imidazole was immobilized on a
gold electrode as set forth in Example 4. After formation of
the SAM, electrodes containing the SAM were placed in a
solution of ZnCl2 (or CoCl) (100 mM) in PBS supplemented
with EDTA (1 mM) for 1 hour. The electrodes were then
rinsed with deionized water and histidine-tagged methylene
blue (His-MB) (10-15 uL of 5 uM solution in PBS) was
dropcasted onto the electrodes for 1 hour. The electrodes were
then rinsed thoroughly by washing with deionized water (1x5
mL), ethanol (1x2 mL), deionized water (1x5 mL), 1 MNaCl
(1 M. 1x2 mL), and deionized water (1x5 mL).
The electrodes were placed in an electrochemical cell con
taining PBS and analysed by ACV. AC voltammograms were
recorded from -0.05 V to -0.45 V vs. Ag/AgCl at 10 Hz and
with an AC amplitude of 25 mV. The electrodes were equili
brated in PBS until a stable methylene blue peak current was
obtained. In the displacement step, captured His-MB was
displaced from the SAM by adding a high concentration of
free imidazole (250 mM in PBS) to the electrochemical cell.
The methylene blue peak current was then monitored for
20-25 minutes. After displacement, the electrochemical cell
was rinsed with deionized water and placed in a fresh aliquot
of PBS for electrode re-equilibration. AC voltammograms
were collected after the monolayer had equilibrated to
achieve a stable methylene blue peak current.
In the replacement step. His-MB was reintroduced to the
SAM construct by incubating the electrodes in a new aliquot
of ZnC1 (or CoC1,) (100 mM in PBS) and EDTA (1 mM) for
1 hour. The electrodes were then rinsed with deionized water

and His-MB (10-15 uL of a 5 uM solution in PBS) was
dropcasted onto the electrodes for 1 hour. The electrodes were
then rinsed thoroughly by washing with deionized water (1x5
mL), ethanol (1x2 mL), deionized water (1x5 mL), 1 MNaCl
(1 M, 1x2 mL), and deionized water (1x5 mL). The electrodes
were subsequently placed in a fresh aliquot of PBS. AC vol
tammograms were collected after the monolayer had equili
brated to achieve a stable methylene blue peak current.
FIG. 4A shows ACV data for His-MB immobilized on an
imidazole-Zn SAM before and after displacement by free
imidazole. FIG. 4B illustrates ACV data for His-MB immo
bilized on an imidazole-Co SAM before and after displace
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ment by free imidazole. As illustrated in this experiment, both
Co(II) and Zn(II) are suitable for immobilization of the sur
rogate probe, His-MB.
Example 7
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In this example, the capacity of histidine and histamine to
displace His-MB from the SAM constructs of the invention
was tested. 1-(11-mercaptoundecyl)imidazole was immobi
lized on a gold electrode as set forth in Example 4. After
formation of the SAM, electrodes containing the SAM were
placed in a solution of NiCl, (100 mM) in PBS supplemented
with EDTA (1 mM) for 30 minutes. The electrodes were then
rinsed with deionized water and histidine-tagged methylene
blue (His-MB) (10-15 uL of 5 uM solution in PBS) was
dropcasted onto the electrodes for 1 hour. The electrodes were
then rinsed thoroughly by washing with deionized water (1x5
mL), ethanol (1x2 mL), deionized water (1x5 mL), 1 MNaCl
(1 M. 1x2 mL), and deionized water (1x5 mL).
The His-MB-bound electrodes were placed in an electro
chemical cell containing PBS and analysed by alternating
current voltammetry (ACV). AC voltammograms were
recorded from -0.05 V to -0.45 V vs. Ag/AgCl at 10 Hz and
with an AC amplitude of 25 mV. The electrodes were equili
brated in PBS until a stable methylene blue peak current was
obtained. In the displacement step, captured His-MB was
displaced from the SAM by adding a high concentration of
free L-histidine or histamine (250 mM in PBS) to the elec
trochemical cell. The methylene blue peak current was then
monitored for 20-25 minutes. After displacement, the elec
trochemical cell was rinsed with deionized water and placed
in a fresh aliquot of PBS for electrode re-equilibration. AC
Voltammograms were collected after the monolayer had
equilibrated to achieve a stable methylene blue peak current.
In the replacement step. His-MB was reintroduced to the
SAM construct by incubating the electrodes in a new aliquot
of NiCl, (100 mM in PBS) and EDTA (1 mM) for 30 minutes.
The electrodes were then rinsed with deionized water and

His-MB (10-15 uL of a 5 uM solution in PBS) was drop
casted onto the electrodes for 1 hour. The electrodes were then
45
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rinsed thoroughly by washing with deionized water (1x5
mL), ethanol (1x2 mL), deionized water (1x5 mL), 1 MNaCl
(1 M, 1x2 mL), and deionized water (1x5 mL). The electrodes
were subsequently placed in a fresh aliquot of PBS. AC vol
tammograms were collected after the monolayer had equili
brated to achieve a stable methylene blue peak current.
FIG. 5A shows ACV data for His-MB immobilized on an
imidazole-Ni SAM before and after displacement by hista
mine, and after replacement with His-MB. FIG. 4B shows
ACV data for His-MB immobilized on an imidazole-Ni
SAM before and after displacement by histidine, and after
replacement with His-MB. As shown, the effectiveness of
displacement of His-MB by histamine is similar to that
observed with imidazole. Histidine is also capable of displac
ing His-MB from the imidazole-Ni SAM.
Example 8
His-Tagged Methylene Blue Immobilized on a
Nitrilotriacetic Acid SAM
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Gold electrodes were primed as set forth in Example 4.
After cleaning, the gold disk electrodes were rinsed with
deionized water, dried with nitrogen and placed directly in a
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150 uM solution of 3:7 N. N.N-Bis(carboxymethyl)-Llysine-12-mercaptododecanamine (C12-NTA): 8-mercapto
1-octanol (C8-OH) solution in ethanol for 10 minutes. Next,
the electrodes were rinsed with ethanol and deionized water
and placed in a 2 mM solution of 8-mercapto-1-octanol over
night. The electrodes were then rinsed with ethanol and

40
0.17 mM Tris-(2-carboxymethyl)phosphine hydrochloride in
deionized water for 1 hour) in ethanol for 10 minutes. Next,
the electrodes were rinsed with ethanol and deionized water

and placed in a 2 mM solution of 8-mercapto-1-octanol for 3
hours. The electrodes were then rinsed with ethanol and
deionized water.

deionized water.

After formation of the self-assembled monolayer (SAM),
electrodes containing the SAM were placed in a solution of
NiCl, (100 mM) in PBS supplemented with EDTA (1 mM)

10

for 30 minutes. The electrodes were then rinsed with deion

electrodes for 1 hour. The electrodes were then rinsed thor

electrodes for 1 hour. The electrodes were then rinsed thor
15

25

ment, the electrochemical cell was rinsed with deionized

water and placed in a fresh aliquot of PBS for electrode
re-equilibration. AC voltammograms were collected after the
monolayer had equilibrated to achieve a stable methylene
blue peak current.
In the replacement step. His-MB was reintroduced to the
SAM construct by incubating the electrodes in a new aliquot
of NiCl, (100 mM in PBS) and EDTA (1 mM) for 30 minutes.
The electrodes were then rinsed with deionized water and

for 30 minutes. The electrodes were then rinsed with deion

ized water and histidine-tagged methylene blue (His-MB)
(10-15 uL of 5 uM solution in PBS) was dropcasted onto the

ized water and histidine-tagged methylene blue (His-MB)
(10-15 uL of 5 uM solution in PBS) was dropcasted onto the
oughly by washing with deionized water (1x5 mL), ethanol
(1x2 mL) and deionized water (1x5 mL). The His-MB
bound electrodes were placed in an electrochemical cell con
taining PBS and analysed by alternating current Voltammetry
(ACV). AC voltammograms were recorded from -0.05 V to
-0.45 V vs. Ag/AgCl at 10 Hz, and with an AC amplitude of 25
mV. The electrodes were equilibrated in PBS until a stable
methylene blue peak current was obtained. In the displace
ment step, captured His-MB was displaced from the SAM by
adding a high concentration of free imidazole (250 mM in
PBS) to the electrochemical cell. The methylene blue peak
current was then monitored for 20-25 minutes. After displace

After formation of the self-assembled monolayer (SAM),
electrodes containing the SAM were placed in a solution of
ZnCl2 (100 mM) in PBS supplemented with EDTA (1 mM)
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His-MB (10-15 uL of a 5 uM solution in PBS) was drop

oughly by washing with deionized water (1x5 mL), ethanol
(1x2 mL) and deionized water (1x5 mL).
The His-MB-bound electrodes were placed in an electro
chemical cell containing PBS and analysed by alternating
current voltammetry (ACV). AC voltammograms were
recorded from -0.05 V to -0.45 V vs. Ag/AgCl at 10 Hz and
with an AC amplitude of 25 mV. The electrodes were equili
brated in PBS until a stable methylene blue peak current was
obtained. In the displacement step, captured His-MB was
displaced from the SAM by adding a high concentration of
free imidazole (250 mM in PBS) to the electrochemical cell.
The methylene blue peak current was then monitored for
20-25 minutes. After displacement, the electrochemical cell
was rinsed with deionized water and placed in a fresh aliquot
of PBS for electrode re-equilibration. AC voltammograms
were collected after the monolayer had equilibrated to
achieve a stable methylene blue peak current.
FIG. 6B shows ACV data for His-MB immobilized on an
TACN-Zn SAM. As shown, His-MB can be successfully
immobilized on a TACN-modified monolayer using Zn(II) as
the metal ion.

casted onto the electrodes for 1 hour. The electrodes were then

rinsed thoroughly by washing with deionized water (1x5
mL), ethanol (1x2 mL), deionized water (1x5 mL). The elec
trodes were subsequently placed in a freshaliquot of PBS. AC
Voltammograms were collected after the monolayer had
equilibrated to achieve a stable methylene blue peak current.
FIG. 6A shows ACV data for His-MB immobilized on an
NTA-Ni SAM before and after displacement by free imida
zole. As shown, His-MB can be successfully immobilized on
a NTA-modified monolayer using Ni(II) as the metal ion. It
was observed that NTA is a highly effective surface immobi
lized ligand for probe capture. In the imidazole system, two
imidazole head groups are desirable to achieve a stable metal
ligand complex, whereas only one NTA ligand is needed for
stabilized metal ligand complex formation. The NTA-Ni
SAM can also withstand the displacement cycle without sig
nificant loss of nickel metal ions, thus a “metal-replacement
step” is not necessary. The captured His-MB probes can be
easily displaced by excess amount of imidazole in the solu
tion and the imidazole ligands can be effectively replaced by
Hist-MB.
Example 9

Example 10
40

Fabricated on an NTA-Ni SAM
Materials
45
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His-Tagged Methylene Blue Immobilized on a
Triazacyclononane SAM
Gold electrodes were primed as set forth in Example 4.
After cleaning, the gold disk electrodes were rinsed with
deionized water, dried with nitrogen and placed directly in a
100 LM solution of C11-bnTACN solution (premixed with

Electrochemical Peptide-Based HIV Sensor
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HS-(CH)-EG-NTA (C11-EG3-NTA) was purchased
from ProChimia Surfaces Sp. (Poland). Monocarboxymeth
ylene blue NHS ester (NHS-MB) was purchased from emp
Biotech GmbH (Berlin, Germany) and the dialysis bag (1000
MW cut-off) was purchased from Spectrum Labs (Rancho
Dominguez, Calif.). The protein probe and target (HIV-1 p24
gag his and HIV-1 p24 antibody) was purchased from
ProSpec Bio (Rehovot, Israel) and was reconstituted in PBS
at a concentration of 76.9 uM and 6.66 uM respectively.
6-mercapto-1-hexanol (C6-OH), Sulphuric acid (95%),
hydrochloric acid, HEPES, trizma base, magnesium chloride,
potassium chloride, calcium chloride, Sodium chloride,
monosodium phosphate, disodium phosphate, nickel (II)
chloride, imidazole, and ethylenediaminetetraacetic acid
(EDTA) were used as received from Sigma-Aldrich (St.
Louis, Mo.) without further purification. Diamond suspen
sion, 0.1 um, was purchased from Buehler (Lake Bluff, Ill.).
All the solutions were made with deionized water (DI
HO), purified through a Millipore Synergy system (18.2
MS2 cm, Millipore, Bedford, Mass.). The phosphate buffer
saline (PBS) used in this study contained 8.02 mMNaHPO,
1.98 mMNaH2PO, 100 mMNaCl, pH 7.4. The Phys2 buffer
used in this study contained 20 mM Tris, 140 mM NaCl, 5
mMKC1, 1 mM MgCl, and 1 mM CaCl pH 7.4.
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Procedure

Procedure

HIV-1 P24 proteins (34.2 LM) were modified using a solu
tion of NHS-MB (2.2 mM) in chilled HEPES (6.7 mM, pH
9.5) by mixing the solution and allowing the solution to sit for
90 minutes with a cold pack in the dark. The solution was then
dialyzed for 4 hours in HEPES (20 mM, pH 9.5) and trans
ferred to a 10 mM solution of HEPES (pH 7.5) overnight.
Gold electrodes were polished and primed as set forth in
Example 4. After cleaning, the gold disk electrodes were
rinsed with deionized water, dried with nitrogen and placed
directly in a 2 mM solution of 1:3 C11-EG3-NTA:C6-OH in

Gold electrodes were primed by polishing with a 0.1 um
diamond Suspension, rinsing with deionized water and Soni
cating in a low power Sonicator for about five minutes to
remove bound particulates. The electrodes were electro
chemically cleaned by a series of oxidation and reduction
cycles in 0.5 MHSO. The area of each electrode was deter
mined by measuring the charge associated with a gold oxide
stripping peak formed after the cleaning process in 0.05 M
HSO.
Before fabricating the monolayer, the dS-Im molecules
were deprotected by allowing solutions containing the com
pounds to incubate for 1 hour. Specifically, Solution A was
prepared to contain either dS1-Im (1.5 mM) or dS2-Im (1.5
mM) in solution with KOH (90mM in EtOH). Solution B was
made after incubating Solution A for an hour by mixing 100
uL of Solution A with 500 uL of 2 mM C8-OH in DI H.O.
FIG. 8 shows the structures for compounds dS1-Im and dS2

5

10

ethanol for 24 hours at 4°C. Next, the electrodes were rinsed

with ethanol and deionized water and dried with nitrogen gas.
After formation of the SAM, electrodes containing the
SAM were placed in a solution of NiCl2 (100 mM) in Tris
HCL (10 mM, pH 8.0) for 30 minutes. The electrodes were
then rinsed with deionized water and HIV-1 P24-MB (10-15
uL of 7.3 uM solution in PBS) was dropcasted onto the

15

electrodes for 1 hour. The electrodes were then rinsed thor

Im.

oughly by washing with deionized water (1x5 mL), 5
TWEEN 20 (1x2 mL) and deionized water (1x10 mL). The
electrodes were then placed in an electrochemical cell con
taining PhyS2 and analysed via alternating current Voltamme
try (ACV). AC voltammograms were recorded from -0.1 V to
-0.4V vs. Ag/AgCl at 10 Hz, and with an AC amplitude of 25
mV. The electrodes were allowed to equilibrate in Phys2 until
a stable MB peak current was obtained. The target, 50 nM
anti-p24 antibodies were added to the Phys2 buffer and moni

After the cleaning process, the gold disk electrodes were
rinsed with deionized water, dried with nitrogen and placed
directly in solution B for 3 hours. Next, the electrodes were
rinsed with ethanol and deionized water and placed in a
solution of NiCl, (100 mM) in Tris-HCl (10 mM) for 30
25

tored via ACV.

FIG. 7 shows ACV data of the sensor prepared in this
experiment in the absence and presence of anti-p-24 antibod
ies. As illustrated in this experiment, His-tagged and MB
modified HIV p24 antigent can be immobilized onto an NTA
NiSAM of the invention. The MB signal is stable and a small
reduction in the MB signal is evident upon addition of the
target anti-p24 antibodies.
Example 11
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His-Tagged Methylene Blue Immobilized on SAMs
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Fabricated with C11-Im, dS1-Im and dS2-Im
Materials

8-mercapto-1-octanol (C8-OH), sulphuric acid (95%),
Sodium chloride, monosodium phosphate, disodium phos
phate, nickel(II) chloride, trizma base, hydrochloric acid, and
ethylenediaminetetraacetic acid (EDTA) were purchased
from Sigma-Aldrich (St. Louis, Mo.) and used as received
without further purification. Diamond suspension (0.1 um)
was purchased from Buehler (Lake Bluff, Ill.). Methylene
blue histidine-tagged peptide: (His-MB) (His-His-His-His
His-His-Lys-Methylene blue) was purchased from Xaia Cus
tom Peptides (Göteborg, Sweden).
All solutions were prepared with deionized water and puri
fied through a Millipore Synergy system (18.2 MS2 cm, Mil
lipore, Bedford, Mass.). The phosphate buffer saline (PBS)
used in this study contained 8.02 mM NaHPO, 1.98 mM
NaH2PO, and 100 mM NaCl (pH 7.4).

45

50

C11-Im, dS1-Im, and dS2-Im is shown in FIG. 9. FIG. 10A
55

Instrumentation

Electrochemical measurements were performed at room
temperature (22+1°C.) using a CHI 1040A Electrochemical
Workstation (CH instruments, Austin, Tex.). Polycrystalline
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gold disk electrodes with a geometric area of 0.0314 cm were

purchased from CH instruments (Austin, Tex.). The counter
electrode (platinum wire electrode) and the reference elec
trode (Ag/AgCl, 3M KCl) were also purchased from CH
Instruments.

minutes. The electrodes were then rinsed with deionized

water and histidine-tagged methylene blue (His-MB) (10-15
uLof5uM solution in PBS, pH 8.0) for 1 hour. The electrodes
were then rinsed thoroughly with PBS.
The His-MB-bound electrodes were placed in an electro
chemical cell containing PBS and analysed by alternating
current voltammetry (ACV). AC voltammograms were
recorded from -0.05 V to -0.5 V vs. Ag/AgCl at 10 Hz and
with an AC amplitude of 25 mV. The electrodes were equili
brated in PBS until a stable methylene blue peak current was
obtained. In the displacement step, captured His-MB was
displaced from the SAM by adding a high concentration of
NiC1 (100 mM in 10 mM Tris-HCl) 250 mM in PBS) to the
electrochemical cell. The methylene blue peak current was
then monitored for 40 minutes. After displacement, the elec
trochemical cell was rinsed with deionized water and placed
in a fresh aliquot of PBS for electrode re-equilibration. AC
Voltammograms were collected after the monolayer had
equilibrated to achieve a stable methylene blue peak current.
To replace probes that were removed in the displacement
step, the electrodes were incubated in a new aliquot of His
MB (5 uM in PBS pH 8.0) for 1 hour. The electrodes were
then rinsed using PBS. The electrodes were subsequently
placed in a freshaliquot of PBS and AC voltammograms were
collected after the monolayer had equilibrated to achieve a
stable methylene blue peak current.
The ACV trace of the His-MB SAM fabricated using
shows the ACV trace of the His-MB SAM fabricated dS1
Im, before and after displacement with Ni(II), and after
replacement with His-MB. FIG. 10B shows the ACV trace of
the His-MB SAM fabricated dS2-Im, before and after dis
placement with Ni(II), and after replacement with His-MB.
As illustrated, the SAMs fabricated in this example can be
used to immobilize histidine-modified peptide probes. The
immobilized probes can be rapidly displaced by incubating
the electrode in a Ni(II) solution. Replacement of the probes
can be easily achieved by immersing the electrode in a new
peptide probe solution.
Various modifications of the invention, in addition to those
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described herein, will be apparent to those skilled in the art
from the foregoing description. Such modifications are also
intended to fall within the scope of the appended claims. Each
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16. The self-assembled monolayer of claim 1, wherein at
least one of R. R. R. and R is CN.
17. The self-assembled monolayer of claim 1, wherein R
and R are OH, C(O)R. N. heterocyclyl, or heteroaryl.
What is claimed is:
1. A self-assembled monolayer comprising a compound of 5 18. The self-assembled monolayer of claim 1, wherein R
Formula II:
and Rare OH.
19. The self-assembled monolayer of claim 1, wherein R
and Ra are heterocyclyl or heteroaryl.
II
20. The self-assembled monolayer of claim 1, wherein R
R
10 and Ra are heterocyclyl.
R-U
s/X-R,
as
21. The self-assembled monolayer of claim 1, wherein R
and Ra are 1.4.7-triazacyclononanyl.
22. The self-assembled monolayer of claim 1, wherein R
R-V
2 Y-R
and Rare heteroaryl.
15
23. The self-assembled monolayer of claim 1, wherein R
wherein:
and Rare pyridyl or imidazolyl.
R-R are each, independently, SR, OH, COR, heterocy
24. The self-assembled monolayer of claim 1, wherein R
clyl, heteroaryl, CN, N or halo:
and Ra are pyridyl.
R is 0-2 R groups;
25. The self-assembled monolayer of claim 1, wherein R
X, Y, U, and V are each, independently, C-Calkyl;
and Ra are imidazolyl.
R is H. Coalkyl, C(O)H, CO (Coalkyl), SH, S(C.
26. The self-assembled monolayer of claim 1, wherein R
20alkyl);
and Ra are azido.
R, is Co-ohydroxyl, Coheterocycloalkyl, Cs-oaryl,
27. The self-assembled monolayer of claim 1, wherein R
Coheteroaryl, or NR'R''.
and Rare CN.
R is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, 25 28. The self-assembled monolayer of claim 1, wherein R,
hydroxyl, halo, haloalkyl, haloalkoxy, cyano, nitro, is 0 Rc groups.
azido, amino, alkylamino, dialkylamino, carboxy, car
29. The self-assembled monolayer of claim 1, wherein:
boxyalkyl ester, carboxy aryl ester, aminocarbonyl,
R and R are SH or SCO (Coalkyl);
alkylaminocarbonyl, dialkylaminocarbonyl, Sulfonyl,
R and Ra are OH:
aminosulfonyl, alkylaminosulfonyl, dialkylaminosulfo 30 X, Y, U, and V are Calkyl; and
nyl, arylsulfonyl.arylsulfinyl, alkylsulfonyl, orarylsulfo
R, is absent.
nyl; and
30. The self-assembled monolayer of claim 1, wherein:
R and R' are each, independently selected from H, sub
R and R are SH or SCO (Coalkyl);
stituted or unsubstituted alkyl,
R and R are OH or N:
or R and R' come together to form a 4-10-membered 35 X, Y, U, and V are Ca1kyl; and
substituted or unsubstituted heterocyclic ring.
R, is absent.
31. The self-assembled monolayer of claim 1, wherein:
2. The self-assembled monolayer of claim 1, wherein at
R and R are SH or SCO (Coalkyl);
least one of R. R. R. and R is SR
3. The self-assembled monolayer of claim 1, wherein at
R and Ra are N:
least one of R. R. R. and R is S(Coalkyl). SC(O)(C. 40 X, Y, U, and V are Calkyl; and
20alkyl), SH, or S(Coalkyl).
R, is absent.
32. The self-assembled monolayer of claim 1, wherein:
4. The self-assembled monolayer of claim 1, wherein at
R and R are SH or SCO (Coalkyl);
least one of R. R. R. and R is SH or SC(O)(Coalkyl).
5. The self-assembled monolayer of claim 1, wherein at
R and Ra are N:
45
X, Y, U, and V are Csalkyl; and
least one of R. R. R. and R is SH.
6. The self-assembled monolayer of claim 1, wherein at
R, is absent.
least one of R. R. R. and R is SC(O)(Coalkyl).
33. The self-assembled monolayer of claim 1, wherein:
R and R are SH or SCO (Coalkyl);
7. The self-assembled monolayer of claim 1, wherein at
least one of R. R. R. and R is SC(O)CH.
R and Rare OH or N:
8. The self-assembled monolayer of claim 1, wherein R 50 X, Y, U, and V are Csalkyl; and
and R2 are SR.
R, is absent.
9. The self-assembled monolayer of claim 1, wherein R
34. The self-assembled monolayer of claim 1, wherein:
and R are S(Coalkyl). SC(O)(Coalkyl), SH, or S(CR and R are SH or SCO (Coalkyl);
20alkyl).
R and Ra are imidazolyl:
10. The self-assembled monolayer of claim 1, wherein R 55 X, Y, U, and V are Calkyl; and
and R are SH or SC(O)(Coalkyl).
R, is absent.
35. The self-assembled monolayer of claim 1, wherein:
11. The self-assembled monolayer of claim 1, wherein R
R and R are SH or SCO (Coalkyl);
and Rare SH.
R and Ra are imidazolyl;
12. The self-assembled monolayer of claim 1, wherein R
60
and R2 are SC(O)(Coalkyl).
X, Y, U, and V are Calkyl; and
13. The self-assembled monolayer of claim 1, wherein R
R, is absent.
36. The self-assembled monolayer of claim 1, wherein:
and Rare SC(O)CH.
14. The self-assembled monolayer of claim 1, wherein at
R and R are SH or SCO Calkyl:
R and Ra are imidazolyl;
least one of R. R. R. and R is OH, C(O)R. N. heterocy
65
clyl, or heteroaryl.
X and Y are each Calkyl:
U and V are each Calkyl; and
15. The self-assembled monolayer of claim 1, wherein at
least one of R. R. R. and R is OH.
R, is absent.
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reference, including patents, patent applications, and publi
cations, cited in the present application is incorporated herein
by reference in its entirety.

